Podcasts about nih

Is the Word of Wisdom more than a health code? Karen Hepworth explores its history, purpose, and promised blessings in Doctrine and Covenants 89-92.SHOW NOTES/TRANSCRIPTSEnglish: https://tinyurl.com/podcastDC234ENFrench: https://tinyurl.com/podcastDC234FRGerman: https://tinyurl.com/podcastDC234DEPortuguese: https://tinyurl.com/podcastDC234PTSpanish: https://tinyurl.com/podcastDC234ESYOUTUBE: https://youtu.be/lWT8GlQDYAcALL EPISODES/SHOW NOTESfollowHIM website: https://www.followHIMpodcast.comFREE PDF DOWNLOADS OF followHIM QUOTE BOOKSNew Testament: https://tinyurl.com/PodcastNTBookOld Testament: https://tinyurl.com/PodcastOTBookBook of Mormon: https://tinyurl.com/PodcastBMBookWEEKLY NEWSLETTERhttps://tinyurl.com/followHIMnewsletterSOCIAL MEDIAInstagram: https://www.instagram.com/followHIMpodcastFacebook: https://www.facebook.com/followhimpodcastTIMECODE00:00 Part 1 - Sister Karen Hepworth01:20 Episode teaser2:01 Karen Hepworth's bio04:24 Come, Follow Me Manual05:37 Big picture before landing the plane09:41 FOOLS!12:29 NIH report on smoking15:40 Wine to water16:50 E-cigarettes, green/black tea, and tobacco prohibition20:47 Conspiring men (and women)24:22 What is a “hot drink?”28:11 Hot drinks, caffeine, chocolate, and coffee questions30:52 Holiness not health34:01 Keeping an eye on our neighbors36:44 The joy in Section 8939:56 God provides to enliven our souls43:20 Cherries, machetes, and tropical fruit44:58 An unusual gift of the Spirit47:23 Meat, waste, and frontier habits52:35 No place for guilt about choices54:49 Gospel Library App and Life Help Topics56:43 Food vs ingredients by young Brother Smith59:38 End of Part I - Sister Karen HepworthThanks to the followHIM team:Steve & Shannon Sorensen: Cofounder, Executive Producer, SponsorDavid & Verla Sorensen: SponsorsDr. Hank Smith: Co-hostJohn Bytheway: Co-hostDavid Perry: ProducerKyle Nelson: Marketing, SponsorLisa Spice: Client Relations, Editor, Show NotesWill Stoughton: Video EditorKrystal Roberts: Translation Team, English & French Transcripts, WebsiteAriel Cuadra: Spanish TranscriptsAmelia Kabwika: Portuguese TranscriptsHeather Barlow: Communications DirectorIride Gonzalez: Social Media, Graphic Design"Let Zion in Her Beauty Rise" by Marshall McDonaldhttps://www.marshallmcdonaldmusic.com

What if your consciousness could literally change your biology? Not just feel better, but test better. Like, bloodwork-better. Atom-better. That's exactly what today's guest, Dahryn Trivedi, claims, and over 660 peer-reviewed studies back her up. In this jaw-dropping, paradigm-shattering episode, Dahryn shares the science behind her Divine Blessings; energetic transmissions that have reportedly transformed lives, health, agriculture, and even the atomic structure of materials.In This Episode, You'll Discover:What happens when you test consciousness in a laboratory settingWhy top institutions like Harvard, MIT, and Oxford are taking noticeThe mind-blowing results of NIH gold-standard trials on motor and cognitive functionHow Divine Blessings reportedly increased anti-aging proteins by over 600%Why faith and science aren't enemies; they're dance partnersWhat enlightenment really is (hint: it's not just green juice and good vibes)Key Quotes: “Consciousness isn't just a concept; it's a programming force that governs atoms, cells, and human potential.” “This is the first clinical trial to show nearly 100% improvement in every parameter of the NIH Cognitive & Motor Function Toolbox.” “You don't need to believe in it for it to work. Even our placebo-controlled trials show the changes are real.” Who Is Dahryn Trivedi? Dahryn Trivedi is an Enlightened Master and internationally recognized spiritual leader. Alongside her husband and guru, Guruji Mahendra Trivedi, she runs Divine Connection International, a nonprofit dedicated to transforming lives through scientifically validated Divine Blessings. Their work spans over 6,000 science experiments and is indexed in institutions like NIH, Stanford, Oxford, and Cambridge. She has spoken at NASDAQ, been featured on ABC, FOX, and The CW, and continues to challenge the boundaries of what we think is possible with the human experience. Proven Benefits of Divine Blessings (As Discussed in the Episode):Boost in anti-aging proteins (Klotho) by over 600%Increased oxytocin, serotonin, and nutrient absorptionImproved cartilage regeneration and joint healthReversal of aging symptoms and immune supportEnhanced cognitive and motor performanceMeasurable vitality in plants and agricultural yields...with no chemicals used

David Waldman and Greg Dworkin take us over the wacko Wednesday hump. Winning! That will be the only conclusion you'll ever be able to draw about the US, from any US source from now on. Everything that the government says henceforth will be consistently useless for every citizen. Stats, science, history, and art will first pass through Donald K. Trump, and those who don't come back for seconds will regret it. (Speaking of crap, don't go to that site. Ron Brownstein, Bruce Bartlett, and of course, Justin Wolfers are on Blue Sky. Heck, you can watch Justin Wolfers on MSNBC, on somebody else's TV, on bsky.app!  Trump wants to know students' race to make certain that the wrong ones don't get extra. The NIH will pivot away from mRNA vaccines, not because they don't work, but because of vibes. Their vibes. CDC projects and careers are shot down as bullets come through their windows. Skateboarders beware! A military presence in Washington DC won't stop murders, car jackings or arson on any block where they aren't standing, and the bubble boys will still be afraid to come out, but DC did vote for Kamala, therefore a bronze likeness of Big Balls will need to be placed at the base of the Washington Monument. Political polls (BTW, follow Political Polls on Blue Sky) indicate some good things upcoming for Dems. Latinos still surviving in the United States are beginning to sour on the Gop. WARs and WARPs are the MVPs. Mamdanimentum is being fueled by Cuomo and Trump, as a list of their scandals can fill a dozen ads. Forget The Apprentice. Ghislaine Maxwell is the reigning champion on The Price is Right, and it's looking good for the Showcase Showdown. Russia, Russia, Russia! Usha Vance may not hate JD now, but why wait on the divorce? Marjorie Taylor Greene makes more than 30 times what she did when she was first elected. How? Go to hell! Maybe her buddy Laura Loomer can take her there.

What if everything we thought we knew about motivating people to exercise was wrong? In this eye-opening episode, we explore the counterintuitive science of sustainable physical activity with behavioral scientist Dr. Michelle Segar and lifestyle medicine physician Dr. Rakesh Jatwani.Here's a shocking revelation: telling patients to exercise "for their health" might actually be sabotaging their long-term motivation. Dr. Segar shares research showing that health-focused exercise messaging can be as demotivating as weight-loss goals, while Dr. Jatwani candidly admits, "I was doing harm in the way I was talking about exercise" before discovering these evidence-based approaches.Both experts take us behind the scenes of their upcoming workshop at the American College of Lifestyle Medicine conference, where they'll present a simple, practical framework for healthcare providers to transform how they discuss physical activity with patients. This framework, grounded in behavioral science yet accessible enough to deploy in time-limited clinical settings, promises to bridge the gap between good intentions and sustainable habits.Ready to transform how you think about physical activity motivation? Listen now, and discover why movement that enhances daily quality of life creates more lasting change than exercise prescribed solely for health benefits.Show Notes Page: https://www.wellnessparadoxpod.com/podcast/episode/146Our Guests: Dr. Michelle Segar, PhD & Dr. Rak Jotwani, MDDr. Michelle Segar is an award-winning, NIH-funded researcher at the University of Michigan with thirty years studying how to help people adopt physical activity and other lifestyle behaviors in ways that can be sustained within the unpredictability of the real world. Since 1994, her scientifically supported methodologies have been transforming peoples' mindsets about lifestyle behaviors in ways that cultivate the daily decision-making that underlies behavioral sustainability.Dr. Rakesh (Rak, pronounced "rock") Jotwani is a board-certified lifestyle medicine physician and the founder of RAK Your Life, a virtual practice dedicated to empowering individuals to make sustainable, evidence-based lifestyle changes. Dr. Jotwani's career has spanned hospital medicine, primary care, and leadership roles, including serving as the Director of Lifestyle Medicine at Kaiser Permanente San Francisco. Follow us on social at the links below: https://www.facebook.com/wellnessparadox https://www.instagram.com/wellnessparadox/ https://www.linkedin.com/company/wellness-paradox-podcast https://twitter.com/WellnessParadox

As we continue this series, we look at the evolving governing head of globalism and how it was founded: the United Nations. This series will pull back the curtain on one of the most powerful institutions in the world.Isaac Kappy Intro: https://x.com/GerardTakiwa/status/1953882091307028660 Trump on Operation Warp Speed: "One of the most incredible things ever done in this country... Everything about it was has been amazing."https://x.com/disclosetv/status/1953212286384128392 RFK Jr: “We're developing a universal vaccine at NIH, which is a vaccine that addresses the entire phylum of viruses.” https://x.com/MazeLove14/status/1953719485409460714

President Trump has federalized Washington DC. Jesse Kelly unpacks what that means. This comes as the FBI and DOJ have made some major moves. Jesse breaks down those moves as well. Joining Jesse on the show is NIH director Jay Bhattacharya to discuss big changes happening. Plus, Buck Sexton breaks down the latest on redistricting efforts. I'm Right with Jesse Kelly on The First TV | 8-11-25 The Fresh Pressed Olive Oil Club: Go to https://FarmFresh246.com & get your first $39 bottle free with no obligation or commitment. Pure Talk: Go to https://www.puretalk.com/JESSETV to make the switchFollow The Jesse Kelly Show on YouTube: https://www.youtube.com/@TheJesseKellyShowSee omnystudio.com/listener for privacy information.

Yes, Trump says the military is coming to NYC, LA and Chicago next to impose ‘law and order’. This is completely unconstitutional and if Biden tried this during his tenure, the right wing influencer class would have absolutely LOST their minds. Instead today, because they continue to worship their Golden God, they are clapping like seals and making fools of themselves with their hypocrisy. Kris Anne Hall has been a consistent warrior for liberty and is a constitutional scholar. This is what she hade today say about Trump’s memorandum: “But here’s the danger: if we normalize federal policing in D.C. under the plea of necessity, it will be used as precedent to spread into the States. Expanding federal policing powers turns them into a standing army. Maybe not under this president, but the next one could use that power to rule America’s streets like a political king. That’s not safety, that’s the road to tyranny.” - @RealKaHall WATCH LIVE HERE: https://rumble.com/c/TheShannonJoyShow Protect your retirement today with GOLD. Click HERE today to get started and see if you qualify for $7500 in free silver! Go to www.colonialmetalsgroup.com/joy Shannon’s Top Headlines, August 12, 2025: Trump’s DC Lockdown Is NOT About Safety - It’s The Road To Tyranny: https://x.com/RealKahall/status/1955073391817527510 NIH Trots Out Promo For NEW Universal Vaccine Platform And Gets Hammered With Comments: https://x.com/NIH/status/1954976649440567362 Ah, Youth: Smartphones Are Ruining Their Brains At Unprecedented Speed: https://www.technocracy.news/ah-youth-smartphones-are-ruining-their-brains-at-unprecedented-speed/ 120 Million Square Feet: Store Closings In The US Are On Pace To Set A New Record High In 2025: https://www.zerohedge.com/personal-finance/120-million-square-feet-store-closings-us-are-pace-set-new-record-high-2025 Shocking, Record Explosion In Student Loan Delinquencies Marks The Start Of Next Debt Crisis: https://www.zerohedge.com/markets/shocking-record-explosion-student-loan-delinquencies-marks-start-next-debt-crisis SJ Show Notes: Please support Shannon’s independent network with your donation HERE: https://www.paypal.com/donate/?hosted_button_id=MHSMPXEBSLVT Support Our Sponsors: The best medicine is chronic GOOD health and achieving it naturally. It’s why my family uses Native Path Collagen every day! Go to getnativepathcollagen.com/joy today to claim your EXCLUSIVE 45% off deal before it’s gone. Geo-engineering schemes are creating WILD weather and you never know when the power or your cell phone could go out! You NEED to be prepared and your one stop shop is The Satellite Phone Store. They have EVERYTHING you need when the POWER goes OUT. Use the promo code JOY for 10% off your entire order TODAY! www.SAT123.com/Joy Please consider Dom Pullano of PCM & Associates! He has been Shannon’s advisor for over a decade and would love to help you grow! Call his toll free number today: 1-800-536-1368 or visit his website at https://www.pcmpullano.com

Yes, Trump says the military is coming to NYC, LA and Chicago next to impose ‘law and order’. This is completely unconstitutional and if Biden tried this during his tenure, the right wing influencer class would have absolutely LOST their minds. Instead today, because they continue to worship their Golden God, they are clapping like seals and making fools of themselves with their hypocrisy. Kris Anne Hall has been a consistent warrior for liberty and is a constitutional scholar. This is what she hade today say about Trump’s memorandum: “But here’s the danger: if we normalize federal policing in D.C. under the plea of necessity, it will be used as precedent to spread into the States. Expanding federal policing powers turns them into a standing army. Maybe not under this president, but the next one could use that power to rule America’s streets like a political king. That’s not safety, that’s the road to tyranny.” - @RealKaHall WATCH LIVE HERE: https://rumble.com/c/TheShannonJoyShow Protect your retirement today with GOLD. Click HERE today to get started and see if you qualify for $7500 in free silver! Go to www.colonialmetalsgroup.com/joy Shannon’s Top Headlines, August 12, 2025: Trump’s DC Lockdown Is NOT About Safety - It’s The Road To Tyranny: https://x.com/RealKahall/status/1955073391817527510 NIH Trots Out Promo For NEW Universal Vaccine Platform And Gets Hammered With Comments: https://x.com/NIH/status/1954976649440567362 Ah, Youth: Smartphones Are Ruining Their Brains At Unprecedented Speed: https://www.technocracy.news/ah-youth-smartphones-are-ruining-their-brains-at-unprecedented-speed/ 120 Million Square Feet: Store Closings In The US Are On Pace To Set A New Record High In 2025: https://www.zerohedge.com/personal-finance/120-million-square-feet-store-closings-us-are-pace-set-new-record-high-2025 Shocking, Record Explosion In Student Loan Delinquencies Marks The Start Of Next Debt Crisis: https://www.zerohedge.com/markets/shocking-record-explosion-student-loan-delinquencies-marks-start-next-debt-crisis SJ Show Notes: Please support Shannon’s independent network with your donation HERE: https://www.paypal.com/donate/?hosted_button_id=MHSMPXEBSLVT Support Our Sponsors: The best medicine is chronic GOOD health and achieving it naturally. It’s why my family uses Native Path Collagen every day! Go to getnativepathcollagen.com/joy today to claim your EXCLUSIVE 45% off deal before it’s gone. Geo-engineering schemes are creating WILD weather and you never know when the power or your cell phone could go out! You NEED to be prepared and your one stop shop is The Satellite Phone Store. They have EVERYTHING you need when the POWER goes OUT. Use the promo code JOY for 10% off your entire order TODAY! www.SAT123.com/Joy Please consider Dom Pullano of PCM & Associates! He has been Shannon’s advisor for over a decade and would love to help you grow! Call his toll free number today: 1-800-536-1368 or visit his website at https://www.pcmpullano.com

Medicine stands at the threshold of a new era, where artificial intelligence and systems biology are working hand in hand to make care more personal, predictive, and precise than ever before. AI is already improving diagnostic accuracy, automating administrative tasks, and uncovering patterns in data—like retinal scans or genomics—that humans often miss. Rather than replacing doctors, AI enhances their ability to deliver more informed, precise, and efficient care. At the same time, individuals are gaining tools—from at-home diagnostics to wearable biosensors—that empower them to track and optimize their own health. This shift marks a move from reactive, disease-centered care to a proactive, data-driven model of scientific wellness. In this episode, I talk with Dr. Eric Topol, Dr. Nathan Price, Dr. Leroy Hood, Dr. Vijay Pande, and Daisy Wolf about how artificial intelligence, personalized data, and wearable technology are converging to radically transform medicine. Dr. Eric Topol is Executive Vice President of Scripps Research and founder/director of its Translational Institute, recognized as one of the top 10 most cited researchers in medicine with over 1,300 publications. A cardiologist and author of several bestselling books on the future of medicine, he leads major NIH grants in precision medicine and shares cutting-edge biomedical insights through his Ground Truths newsletter and podcast. Dr. Nathan Price is Chief Scientific Officer at Thorne HealthTech, author of The Age of Scientific Wellness, and a National Academy of Medicine Emerging Leader. He also serves on the Board on Life Sciences for the National Academies and is Affiliate Faculty in Bioengineering and Computer Science at the University of Washington. Dr. Leroy Hood is CEO and founder of Phenome Health, leading the Human Phenome Initiative to sequence and track the health of one million people over 10 years. A pioneer in systems biology and co-founder of 17 biotech companies, he is a recipient of the Lasker Prize, Kyoto Prize, and National Medal of Science. Dr. Vijay Pande is a General Partner at Andreessen Horowitz and founder of a16z Bio + Health, managing over $3 billion in life sciences and healthcare investments at the intersection of biology and AI. An Adjunct Professor at Stanford, he is known for his work in computational science, earning honors like the DeLano Prize and a Guinness World Record for Folding@Home. Daisy Wolf is an investing partner at Andreessen Horowitz, specializing in healthcare AI, consumer health, and healthcare-fintech innovation. She previously worked at Meta and in various startups, holds a JD from Yale Law, an MBA from Stanford, and a BA from Yale, and is based in New York City. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: Can AI Fix Our Health and Our Healthcare System? The Next Revolution In Medicine: Scientific Wellness, AI And Disease Reversal The Future of Healthcare: The Role of AI and Technology

The year 2025 has seen the most aggressive moves ever by the US executive branch against scientific research as the Trump Administration has gutted federal science and regulatory agencies and cancelled billions of dollars in research grants that had already been awarded to universities. With me to discuss the Trump Administration attacks on university research is Claudia Polsky. Claudia is a clinical professor of law and the founding director of the Environmental Law Clinic at the University of California, Berkeley.

Donnelly L. McDowell, Katie Rogers, Andrea deLorimier Robert F. Kennedy Jr. promised big changes as Secretary of the Department of Health & Human Services, the sweeping agency that oversees FDA, NIH, CDC, and other divisions and agencies. Five months into his tenure, he has launched a number of initiatives that target certain types of food products and ingredients. The changes invited by the so-called ​“MAHA” or ​“Make America Healthy Again” movement have not been limited to the federal level – with certain states passing or proposing legislation banning or limiting the use of certain foods and ingredients, or requiring warning labels akin to California's Proposition 65.

Anytime I'm this excited on the mic, you already know why—there's a Doctor Coach School™ student in the building. And today, we're catching up with someone you've met before: Dr. Rasheeda Hall, physician scientist, grant-writing expert, and the founder of Make Internal Shifts.Since her last visit, Dr. Rasheeda has:Gone from a $6K offer to confidently selling her $10K package.Filled her 1:1 roster and decided to launch her first group program (starting September 2025).Rebuilt her intellectual property into a clear, structured curriculum her clients—and she—love.Balanced being an NIH-funded researcher, clinician, mom, and business owner without burning out.We talk about:The exact moment she chose growth over comfort (and why most people don't).How “feeling feelings” is a business skill no one teaches you in med school.The nerves, silence, and self-trust behind her first $10K sales call.Her surprising link between submitting major research grants and making big moves in her coaching business.Why she used ChatGPT as a thought partner (not a content factory) to refine her IP.If you've ever wondered how to raise your prices, protect your nervous system in sales, or transition from 1:1 to group without losing your magic, this conversation is your blueprint.Connect with Dr. Rasheeda:

Send us a textCould a simple apricot seed hold the key to preventing and addressing cancer? John Richardson believes so, and he's carrying forward a 60-year family legacy that's been systematically suppressed by medical authorities.Richardson reveals the shocking story of how his father, a medical doctor, was repeatedly jailed and had his practice raided for helping thousands of patients overcome cancer using natural methods. The reason? He promoted Laetrile (vitamin B17) and other natural approaches that threatened the trillion-dollar cancer industry.What makes this conversation truly groundbreaking is Richardson's explanation of cancer as a metabolic deficiency disease—not something you catch or inherit genetically. He presents compelling evidence about the Hunza people who live well beyond 100 years while consuming up to 200 apricot seeds daily, and points to recent NIH studies confirming that amygdalin (found in apricot seeds) causes cancer cell death.The landscape is changing rapidly. Richardson shares how forward-thinking doctors are achieving remarkable results with cancer patients using Laetrile injections, ozone therapy, and hyperbaric oxygen—addressing cancer's vulnerability in low-oxygen environments. He also highlights a new medical school funded by a Walton family member that focuses 80% of its curriculum on nutritional approaches to disease rather than pharmaceutical interventions.This isn't just about cancer—it's about reclaiming control over our health in an age of medical dogma. Richardson explains how COVID-19 has accelerated public awakening, brSUPER FUEL ENERGY DRINKA BLAST OF PREMIUM NATURAL ENERGY! Freedom Flag and PoleWe don't just sell flags. We honor America! Thank you for visiting Freedom Flag & Pole! Excel RoofingExcel RoofingInstacart - Groceries delivered in as little as 1 hour.Free delivery on your first order over $35.Allswell - Your Dream Bed Starts HereFree delivery on your first order over $35.Buzzsprout - Let's get your podcast launched!Start for FREEGene German Certified Firearms Instructor - Minnesota, Wisconsin, Illinois, Floridagraithcare.comGraith Care Independent Patient Advocate medical advocacy, consultation, advice US and InternationalOH EDDIES WHISKEY BOURBON SAUCEOh Eddies Sweet Whiskey Bourbon Sauce is guaranteed to step up your next barbeque. Made in MinnesotaDisclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show Thank you for listening to this episode of HuttCast, the American Podcast. We hope you enjoyed today's discussion and gained valuable insights. To stay updated on our latest episodes, be sure to subscribe to our podcast on your preferred listening platform. Don't forget to leave us a rating and review, as it helps others discover our show. If you have any comments, questions, or suggestions for future topics, please reach out to us through our website or social media channels. Until next time, keep on learning and exploring the diverse voices that make America great.

The mechanisms behind Alzheimer's disease have eluded scientists for decades. But a new breakthrough points to lithium as a possible explanation—not only does it occur naturally in the brain, but a deficiency causes dementia in mice. This research is one of thousands of projects that have lost funding due to President Trump's cuts to the National Institutes of Health (NIH). Host Ira Flatow speaks with Alzheimer's researcher Bruce Yankner about this new finding, and then to epidemiologist Katelyn Jetelina and immunologist Elisabeth Marnik about the country's “quiet engine of science,” the NIH.Guests: Dr. Bruce Yankner is professor of genetics and neurology at Harvard Medical School in Boston, Massachusetts.Dr. Katelyn Jetelina, epidemiologist and author of the Your Local Epidemiologist newsletter. She's based in San Diego.Dr. Elisabeth Marnik is an immunologist and Director of Science Education & Outreach at the MDI Biological Laboratory in Bar Harbor, Maine.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

It's Thursday, August 7th, A.D. 2025. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark and Adam McManus Pakistani Christian died after years of neglect in prison International Christian Concern reports that a 25-year-old Christian man in Pakistan died last Thursday after years of neglect in prison. When he was 16, Nabeel Masih was accused of posting an image on Facebook, allegedly insulting an Islamic holy site. Police deleted the post, erasing any evidence of what he actually posted. He was sentenced to 10 years in prison, becoming the youngest person convicted of blasphemy against Islam in the country.  Pakistan's Supreme Court granted Masih bail in 2020. However, he had already suffered years of neglect, abuse, and lack of medical care, leading to his recent death. Psalm 116:15 says, “Precious in the sight of the LORD is the death of His saints.” Billy Graham Association helping defend European Christians The Billy Graham Evangelistic Association is extending its legal defense fund to Christians across Europe. Evangelist Franklin Graham started the fund for defending religious freedom in the United Kingdom. This came after he won multiple lawsuits against British venues that cancelled their events. The fund has grown to $1.3 million. Franklin Graham told Fox News Digital, “We took the damages that we won through BGEA's court cases in the U.K., and put those funds into the Billy Graham Defense Fund — a new ‘war chest' to help other Christians in Europe who are threatened or intimidated into silence and not expressing their faith.” Army Sergeant shot 5 co-workers on Georgia Army base Bad news from a U.S. Army base in Georgia. LUBAS: “An active duty soldier assigned to Fort Stewart, Georgia, shot and wounded five of his fellow soldiers here on Fort Stewart. Thankfully, all are in stable condition and all are expected to recover.” That was Brigadier General John Lubas on Wednesday afternoon. The soldier shooter has been identified as Army Sergeant Quornelius Radford, reports The U.S. Sun. Radford, age 28, is in custody after he allegedly opened fire at his workplace at the 2nd Armored Brigade Combat Team area just before 11:00 am. The base was briefly locked down. Police said they have not learned more about his motive. Here's the good news. LUBAS: “I would also like to thank the brave soldiers who immediately intervened and subdued the shooter. These soldiers, without a doubt, prevented further casualties.” Planned Parenthood closes only two abortion mills in Louisiana Planned Parenthood is closing its only two locations in Louisiana.  The abortion giant operated in the state for 40 years previously.  Ben Clapper, the executive director of Louisiana Right to Life, told LifeNews, “Effective September 30th, Planned Parenthood will close both its New Orleans and Baton Rouge facilities. What a powerful victory for life. … To each of you who have prayed, volunteered, given, and stood with us—thank you!” With the two closures, Planned Parenthood has closed a total of 40 abortion mills this year. U.S. Health Dept cancels $500 million of mRNA vaccine projects The U.S. Department of Health and Human Services announced Tuesday that it is cancelling $500 million worth of mRNA vaccine development projects. The department said it will focus instead on “platforms with stronger safety records and transparent clinical and manufacturing data practices.” Listen to comments from HHS Secretary Robert F. Kennedy Jr. KENNEDY: “Most of these shots are for flu or COVID, but as the pandemic showed us, mRNA vaccines don't perform well against viruses that infect the upper respiratory tract. … “After reviewing the science and consulting top experts at NIH and FDA, HHS has determined that mRNA technology poses more risk than benefits for these respiratory viruses.” 28% of school boards referenced DEI in second quarter The school tracking website Burbio reports that the prevalence of Diversity, Equity, and Inclusion terms in district school board meetings is down. The Trump administration has prohibited federal funding to recipients that engage in unlawful discrimination practices. This includes DEI programs. During the second quarter of this year, only 28% of school boards referenced such DEI terms, down from 38% last year. Gunman opened fire at a Seattle church event And finally, an unidentified gunman opened fire on a church event in Seattle last Thursday, July 31st.  Tragically, he killed 28-year-old LeBron Givaun near the steps of the church as he arrived with his family at the young adult service at Pursuit Church. He had just gotten married a week earlier and had converted to Christianity just this year. A GoFundMe campaign for LeBron's family has already raised over $70,000. The unidentified suspect reportedly shot the victim in the chest before fleeing the scene in a white Hyundai Elantra with black wheels and a damaged passenger window, reports The Daily. It's not the first time the church has faced attacks. Rioters assaulted church members at a worship event earlier this year.  Listen to comments from Russell Johnson, the pastor of Pursuit Church. JOHNSON: “The thugs who committed this crime were trying to send a message: no church is safe, no house of worship is sacred. The enemy would love for us to back down and hide, but that is simply not who we are. “And although the blood of LeBron is still stained on the front steps of our building, I'm here today to tell you there is a blood that speaks a better word. And it is the precious blood of Jesus that covers us today and provides forgiveness, protection, blessing, and healing.” Revelation 12:11 says the church overcame the Devil “by the blood of the Lamb and by the word of their testimony, and they did not love their lives to the death.” Close And that's The Worldview on this Thursday, August 7th, in the year of our Lord 2025. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Send us a textWe often hear about heart disease prevention, but stroke—a condition nearly as common and often more disabling—gets far less attention. In this episode, Dr. Bobby is joined by cardiologist Dr. Anthony Pearson to uncover what science really says about stroke prevention, the distinct types of strokes, and what practical steps you can take today to lower your risk.Together, they explore the two major types of stroke—ischemic and hemorrhagic—and explain why strokes caused by clots or vessel rupture can have very different causes and consequences. The data shows nearly 800,000 Americans experience strokes annually, and about half of survivors live with long-term disability (CDC; NIH). Yet most of us are unaware of the modifiable risk factors that account for up to 90% of stroke risk (INTERSTROKE Study).Dr. Pearson emphasizes the number one culprit: high blood pressure. It triples individual risk and contributes to half of all strokes, with randomized trials like SPRINT showing that aggressive control reduces both stroke and mortality (SPRINT Study). Both doctors also discuss physical activity—while Dr. Bobby cites strong associations between exercise and reduced stroke risk (BMJ Review), Dr. Pearson cautions that current evidence is largely observational and inconclusive.They also explore the role of lipid levels, citing that high ApoB or LDL may increase risk in strokes caused by carotid atherosclerosis, but not necessarily in cardioembolic strokes. Dietary improvements, particularly following a Mediterranean-style diet, have shown benefits, including reduced stroke risk in randomized trials like PREDIMED.Beyond traditional risk factors, they also explore loneliness as a newer area of concern. A recent study linked persistent loneliness in adults over 50 to a 50% increased stroke risk (Lancet eClinicalMedicine), highlighting the complex social and behavioral factors at play.Dr. Pearson discusses atrial fibrillation (AFib) and why it's a key cause of cardioembolic strokes—especially relevant given that wearables like Apple Watch now help detect AFib early. They also touch on controversial screening approaches, warning against routine carotid ultrasounds and unwarranted treatment of asymptomatic brain aneurysms.Importantly, Dr. Bobby highlights the signs of stroke—sudden weakness, numbness, speech difficulties, or confusion—and urges immediate ER visits to enable timely treatment like thrombolysis, ideally within four hours of symptom onset.As always, they wrap by challenging popular myths. Dr. Pearson explains why aspirin, once widely promoted for primary prevention, is no longer recommended due to increased bleeding risk, especially into the brain. He also debunks the idea that supplements like fish oil or B vitamins help prevent strokes, noting no benefit in recent large trials.Takeaways:Know your blood pressure and cholesterol levels—and treat them if needed. These remain the top modifiable risks for stroke.Prioritize physical activity, even if trial data is imperfect—it benefits vascular health broadly and may reduce stroke risk.Stay socially connected: chronic loneliness has emerging links to stroke risk, highlighting that prevention isn't just physical—it's relational.To continue learning how to live long and well, visit drbobbylivelongandwell.com.

Dr. Sumanta (Monty) Pal and Dr. Kimmie Ng discuss the disturbing rise of early-onset gastrointestinal cancers, the unique challenges faced by younger patients, and key research that is shedding light on potential drivers of early diagnoses in colorectal cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello, everyone. I'm Dr. Monty Pal, and I'm a medical oncologist and professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. I'm really delighted to welcome you all to the ASCO Daily News Podcast as the show's new host. I'll be bringing you discussions with leaders in the oncology space on a variety of topics. I've been working hard with the ASCO team on picking the ideal topics to bring to you, and I'm really delighted to introduce my first guest, a dear friend, Dr. Kimmie Ng, to discuss this huge problem that we're seeing nowadays of early-onset GI cancers. Dr. Ng is the associate chief of the Division of Gastrointestinal Oncology at the Dana-Farber Cancer Institute, and she's an associate professor of medicine at Harvard Medical School in Boston. She serves as co-director of the Colon and Rectal Cancer Program. She's also the founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber. I'm sure we'll talk a little bit about that today.  Just to note, our full disclosures are available in the transcript of this episode.  Dr Ng, it's so great to have you on the podcast. Thanks so much for joining us. Dr. Kimmie Ng: Thank you so much for having me. It's great to be here. Dr. Sumanta (Monty) Pal: I'm going to refer to you as Kimmie, if you don't mind, for the rest of the podcast here. Please, we'll go by first names, if you don't mind.  Your research has really done so much to help improve our understanding of early-onset GI cancers. You've done a lot of work to increase awareness in this space. I don't think there's a couple of months that passes by when I don't see you on television on Good Morning America or other shows really broadcasting this really critical message. I think there's a certain sensitivity that we all have to this issue, right? I mean, because receiving a cancer diagnosis at any age is very challenging, but I'm sure that young patients who face a colorectal cancer diagnosis have some very unique challenges. Could you give us a sense of some of those? Dr. Kimmie Ng: I think the other reason why so many people are interested in this and feel touched by this is that it's not just gastrointestinal cancers that are increasing in young people, but actually a multitude of different cancers have been rising in young individuals. And while it is difficult at any age to receive a cancer diagnosis, we do all know that young people getting a diagnosis like this do face unique challenges. Studies have shown that over 80% have children under the age of 18 when they are diagnosed with colorectal cancer, for example, under the age of 50. And many experience career and education disruptions. They are in what we call the ‘sandwich generation,' where they're not only taking care of young families or starting to think about starting a young family, but they're also taking care of elderly parents. So it's just a very busy stage of life, and to then be facing a usually terminal cancer diagnosis, it is extremely challenging. The other factors that we've seen that seem to be unique or more prevalent in young patients is that there are higher levels of psychosocial distress, depression, and anxiety, and a majority of patients do need medical attention and treatment for those things, whether it's medication treatment or whether it's counseling or support from psychosocial oncologists. And so the other big issue is fertility. We know that so many of the treatments that these young patients receive do permanently and negatively impact fertility. And for a person who is young, who may still be trying to expand their family or again start a family, it is very important that these young patients do receive counseling about fertility preservation prior to starting treatment. Dr. Sumanta (Monty) Pal: You know, it's so interesting you bring this up, and I think about a patient who's in their 40s diagnosed with this disease. They're in the same demographic as I am, as you are. You know, I'm 44 years old, and you know, I'm thinking about my 11- and 12-year-old and my aging parents, right? I mean, the dilemmas that you highlighted are precisely what I'm facing in life, and it's so true, right? If I had to take my day-to-day and superimpose on that a colorectal cancer diagnosis, it would just be problematic in so many spheres, so many spheres. Dr. Kimmie Ng: Absolutely. And because we did think going into this, starting our Young-Onset Colorectal Cancer Center, that these patients will need unique supports, we did conduct a qualitative study and held some focus groups of young-onset colorectal cancer patients as well as their caregivers. And we really identified four primary themes that I think reflect a lot of the experience of patients with cancer, no matter what type of cancer when they're diagnosed young. And the first is the need, feeling overwhelmed by the healthcare system, and the need for patient navigation. As we know, a lot of these patients are previously healthy before they're facing this very serious diagnosis. The second is the need for peer-to-peer support, where they really value connecting with other young patients going through a similar experience. The third, we talked about already, the need for kind of formal psychosocial support in the form of psychosocial oncologists or psychiatrists or social workers. And the last is an interest in research. They are really very invested in getting germline genetic testing as well as somatic genomic profiling to help guide their therapy. Dr. Sumanta (Monty) Pal: That's really encouraging to hear that they themselves are interested in participating in research. I mean, obviously, that's a great way to move the field forward. I view your area of work here as being such a vexing problem because no matter what way you slice it, young-onset colorectal cancer still remains a relatively small proportion of all diagnoses. So how do you go about studying this phenomenon? I mean, it must be challenging to really sort of investigate underlying causes when ostensibly this is still a small piece of the pie. Dr. Kimmie Ng: That is such a great question and is one of the challenges me and my research team think about every single day. As you mentioned, one of the major barriers is that although these cancers are rising in young people, the absolute number of patients being diagnosed is still relatively small, and if it's going to take large scale epidemiologic studies to really understand, for example, what the dietary and lifestyle risk factors are, you need a considerable number of patients in order to have enough power to reach definitive conclusions.  And so this is where it is so important to collaborate. Any single institution is not going to see enough young-onset patients with colorectal cancer to be able to do this work on their own. And so I have really been intent on establishing an international prospective cohort study of patients with young-onset colorectal cancer so that we can increase the numbers of patients we partner with to try to answer these questions, but also so that we can study this on a global scale, because unfortunately this is not something that's just plaguing the United States. It is actually happening in multiple countries around the world. So that is one barrier.  The second, I would say, is that we think it's early life exposures to whatever environmental factor it is that's causing the rise that is likely contributing the most. And so if you imagine how difficult it would be to start studying individuals from when they're children through adolescence, through adulthood, and then all the way until a cancer diagnosis is obtained, a study like that would take too long, would cost too much, and really wouldn't be feasible. So we need to think of alternative ways to really try and answer this question of what is driving this rise in young-onset colorectal cancer. Dr. Sumanta (Monty) Pal: Honestly, Kimmie, this seems like almost an unfair question in the context of what you just mentioned, the challenges in terms of ascertaining causality, right? I'll tell you, I cheated a little bit ahead of this podcast. Kimmie and I had dinner together in Los Angeles a couple months ago. She came out to deliver a Presidential Lectureship at City of Hope. We were delighted to have her. And we did have a couple of thoughts exchanged over potential drivers of these early diagnoses, leaning on perhaps one of the things that you and I are both interested in, the microbiome. But amongst all these things, vitamin D, microbiome, etc., and I won't hold you to this, do you have at least a general sense of what might be contributing to this early-onset phenomenon? Dr. Kimmie Ng: Yeah, as we talked about during my visit there to City of Hope, we do hypothesize that it is a complex interaction between our exposome, which is everything we are exposed to in our environment, which does include diet and lifestyle factors, interacting with host immunity and antitumor immunity, and as well as the microbiome and shaping the composition and diversity of the gut microbiome that are likely interacting to increase susceptibility to colorectal cancer at a younger age. And I will say one of the biggest discoveries, if you will, about what might be driving young-onset colorectal cancer was published a few months ago in Nature. And that paper identified a specific mutational signature caused by the genotoxin colibactin, which is often produced by an organism called pks+ E. coli, as being much more prevalent in younger patients with colorectal cancer than older patients. And so while it doesn't explain necessarily all of young-onset colorectal cancer and why it's rising, it does give us a clue that the microbiome is likely very important in perhaps why this is rising in young people. Dr. Sumanta (Monty) Pal: After you mentioned it, I went back and dove deep into that paper. I was fascinated, fascinated by the content there. And this is just a massive exploration across thousands of patients worldwide. So, I mean, if there is a way to get at least some hint of what's driving this phenomenon, I suppose that's it. So thank you for pointing me in the direction of that manuscript. Now that we've addressed the issue of diagnosis, if we could just, you know, verge on the topic of treatment, right? And this is something that I struggle with. When I have my young patients with kidney cancer, I don't know necessarily that my treatment paradigm changes a whole heck of a lot. I guess what I will say is I might be a little bit more aggressive about concepts like definitive management with surgery. I suppose perhaps their treatment tolerance is a little bit higher. But tell us about the setting of young-onset colorectal cancer. Is the philosophy any different in terms of the actual sort of management of these patients? Dr. Kimmie Ng: That's a great question, and actually I was honored to participate in the first international consensus guidelines group to try to come up with uniform recommendations for how to treat young patients with colorectal cancer. And you know, the overall consensus is just as you said, the medical care of these young patients right now is really not that much different than that of an older patient with colorectal cancer. There are a couple of distinctions. One is that all young patients should get germline genetic testing, given that there is a higher prevalence of pathogenic germline variants when you are diagnosed at a young age. And the second is what we've already talked about, which is that all young patients should be referred for counseling about fertility preservation prior to starting treatment. But otherwise, the chemotherapy regimens recommended, you know, surgery, radiation, all of that seems very similar to older patients. I will say that because most of our young patients with colorectal cancer are diagnosed with left-sided cancers, including rectal cancers, where some of the treatment may be morbid and result in lifelong complications, we do consider de-escalation of therapy and try to consider the long-term implications when it's safe to do so and won't compromise outcomes. The other concerning thing is that younger patients don't necessarily have a better prognosis than older patients. And multiple studies have shown this, that even though we both often treat younger patients more aggressively – they more often receive multi-agent chemotherapy, and more often undergo surgery and radiation – their survival is not necessarily correspondingly better than an older patient with colorectal cancer. So that suggests to us that maybe these cancers are indeed biologically different and perhaps more aggressive or perhaps less responsive to treatment. And so that is some of the focus of our research too, to understand what is actually different about these cancers and how they respond to treatment. Dr. Sumanta (Monty) Pal: It's such a paradox, isn't it, right? Because you just brought this to my mind. I guess on the one hand, our younger patients may be able to tolerate perhaps a greater amount of chemotherapy, targeted therapy, etc. But you're absolutely right. I mean, they do sort of have these lingering issues with side effects that may persist for much longer than the 80- or 90-year-old that we're treating in the clinic. I mean, these tend to be sort of lifelong consequences and sequelae that they're dealing with. So that really does evolve to be a challenge. You've kind of changed my mindset there a little bit. Dr. Kimmie Ng: Yeah, I do think survivorship issues and long-term complications of therapy do need to be considered, especially for a young person who we hope will live a very, very long time. And so part of the work that our Young-Onset Colorectal Cancer Center is doing, we are participating in a pilot navigation study where we navigate patients to survivorship earlier than we typically would, perhaps, for an older patient. And that's so we can get a head start on addressing some of those potential complications of therapy and hopefully mitigate them so that they don't become an issue long term. Dr. Sumanta (Monty) Pal: Do you think there's a role for de-escalation studies formally in these young populations of patients? Dr. Kimmie Ng: I think de-escalation studies are important overall, and specifically for locally advanced rectal cancer, which again is one of the most common types of colorectal cancer diagnosed in our young patients, there are certain populations that may be able to forgo the radiation treatment to the pelvis, for example, and there's more and more patients who now may become candidates for non-operative management where they may not necessarily need to have their rectal cancer surgically removed. And elimination potentially of both of those modalities of treatment can really avoid some of the most serious and morbid complications that often occur with these treatments. Dr. Sumanta (Monty) Pal: Really interesting. Now, this is not and will never be a political podcast, but you know, obviously we're dealing with the consequences of changes on funding and so forth that have evolved over time. And I think it's worth sort of speculating how the landscape of research may change on account of that. Could you comment perhaps a little bit on how some of the funding cuts that we've seen recently at the NIH might affect the body of work that you're so integrally involved in? Dr. Kimmie Ng: I am honestly very worried about the current funding environment. Colorectal cancer is the third most commonly diagnosed cancer among men and women in the United States and globally, and when you combine men and women together, the second leading cause of cancer death. But proportionally, we receive much less funding for colorectal cancer compared to other cancer types. And my thoughts have always been that perhaps this is because there is this stigma around colorectal cancer and maybe some of the symptoms associated with colorectal cancer. And so on top of that, to have additional challenges in obtaining funding, I worry what it will do to the pace of progress for especially young patients with this disease. Also, because of some new stipulations that perhaps international collaborations are being discouraged, I also worry about that aspect of it because young-onset colorectal cancer and gastrointestinal cancers in general is a global phenomenon happening in multiple countries around the world. And if we are to understand what the environmental factors are affecting the different rates of rise in these different countries, we do so much need that international collaboration. So yes, I am worried, and I do hope that conversations like this will spark an awareness of the need for more funding and continued funding into this disease. Dr. Sumanta (Monty) Pal: I will say that, and the audience can't see this because this is an audio program, but I'm wearing my Southwest Oncology shirt here, a SWOG, and it's one of the National Cancer Institute-funded cooperative groups. And you know, I was recently dismayed to find that, you know, funding got cut for international collaborations and enrollment in South America and Latin America. And this was traditionally actually a mainstay of our enrollment for many trials, including trials in rare cancers that present themselves in younger patients in the GU space. So, I completely agree with you. We've got to do something to address this funding issue to make sure that this body of work, both yours and mine, continues, without a doubt. Kimmie, this has been a delightful conversation. I really want to thank you for, you know, leading the charge in the young-onset colorectal cancer space, and you've done so much tremendous work here. Dr. Kimmie Ng: Thank you for having me. Dr. Sumanta (Monty) Pal: If you value the insights that you hear on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. And again, thank you for joining us today. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:   Dr. Sumanta (Monty) Pal @montypal Dr. Kimmie Ng @KimmieNgMD Follow ASCO on social media:    @ASCO on Twitter   ASCO on Bluesky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Sumanta (Monty) Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Kimmie Ng: Honoraria: Seagen, GlaxoSmithKline Consulting or Advisory Role: CytomX Therapeutics, Jazz Pharmaceuticals, Revolution Medicines, Abbvie, Bayer, Pfizer, Agenus, Johnson & Johnson/Janssen, Etiome, AstraZeneca Research Funding (Inst.): Pharmavite, Janssen Other Relationship: JAMA

Aujourd'hui, Coach Lee & Coach Sim reçoivent pour la 2e fois Kristof Robert, ancien bodybuilder de compétition, massothérapeute et coach en PNL.Dans cet épisode, nous discutons de:- Comment changer soi-même peut aider les autres à changer comment ils sont envers toi- La différence entre dire "je ne PEUX pas" et "je ne VEUX pas"- Prendre responsabilité de ses victoires implique de prendre responsabilité de ses défaites aussi- L'importance d'établir et imposer ses limites- "Dans la vie, on a ce qu'on PENSE qu'on mérite"- La différence entre "il FAUT" et "je VEUX"- Bien plus!Bonne écoute!Pour nous suivre:Kristof: @kristofholistikCoach Lee: @coach.lee__ Coach Sim: @coachsim.lat Utilisez le code "WUACV10" pour économiser 10% sur votre commande NIH sur le site ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://nihsupp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Utilisez le code "WUACV10" pour économiser 10% sur votre commande MACHINE sur le site https://project-machine.com/

Dr. Katherine Roe reveals how PETA forced the recent UMass-Amherst Monkey Lab Shutdown. It took four persistent years and many PETA members to stop the cruelty of researcher Agnes Lecreuse. Go to PETA.org for more. See this on YouTube.com/@emilamok1

The first complete draft of the human genome was published back in 2003. Since then, researchers have worked both to improve the accuracy of human genetic data, and to expand its diversity, looking at the genetics of people from many different backgrounds. Three genetics experts join Host Ira Flatow to talk about a recent close examination of the genomes of 65 individuals from around the world, and how it may help researchers get a better understanding of genomic functioning and diversity.Guests:Dr. Christine Beck is an associate professor of genetics and genome sciences in the University of Connecticut Health Center and the Jackson Laboratory.Dr. Glennis Logsdon is an assistant professor of genetics and a core member of the Epigenetics Institute at the University of Pennsylvania.Dr. Adam Philippy is a Senior Investigator in the Center for Genomics and Data Science Research at the National Human Genome Research Institute at the NIH.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Today's guest, Amita Sharma, shares her deeply personal experience with perimenopause in the corporate world, the mental health toll it took, and how she turned that struggle into NourishDoc, a global wellness platform for women 40 and over. This award-winning episode of Sh!t That Goes On In Our Heads brings you a powerful, eye-opening conversation about the intersection of menopause, mindfulness, and mental health. With over 2 million downloads, we are proud to be the 2024 People's Choice Podcast Award Winner for Health and the 2024 Women in Podcasting Award Winner for Best Mental Health Podcast. We want to hear from YOU. Drop us a voice message or leave your thoughts at:https://castfeedback.com/67521f0bde0b101c7b10442a Mental Health Quote:"The sooner you embrace yourself, the sooner you start living your truth. Otherwise, you're just wearing a mask." — Amita Sharma What This Episode CoversAmita opens up about the invisible toll of perimenopause, from brain fog and depression to sleep deprivation and lost libido—all while trying to survive in a high-stakes, male-dominated tech career. We explore how mindfulness, acupuncture, holistic nutrition, and boundary-setting became her survival tools, and how that journey became the seed for NourishDoc. This comprehensive wellness platform helps thousands of midlife women worldwide. SEO Keywords:Menopause mental health, perimenopause anxiety, midlife women support, mindfulness for menopause, holistic wellness, mental health for women over 40, Amita Sharma, NourishDoc Meet Our Guest: Amita SharmaA former high-tech executive turned wellness innovator, Amita Sharma is the founder of NourishDoc. Her lived experience as a perimenopausal woman in corporate America ignited a mission to support other women through the mental and physical chaos of midlife. NourishDoc offers integrative, evidence-based programs for women 35+, tackling sexual health, menopause symptoms, mental clarity, and long-term chronic condition prevention. Amita's Links:Website: http://www.nourishdoc.com/Facebook: https://www.facebook.com/Nourishdoc/X (Twitter): https://x.com/nourishdocYouTube: https://www.youtube.com/@nourishdocInstagram: http://www.instagram.com/nourish_docLinkedIn: https://www.linkedin.com/in/amita-sharma-nourishdoc/ Key Takeaways: Perimenopause isn't just hot flashes—it deeply impacts mental health, identity, and daily functioning. Holistic wellness tools, such as yoga, journaling, and red-light therapy, can help restore balance. There's a serious education gap in healthcare—many doctors are not trained to recognize or treat perimenopause. Actionable Tips from Amita: Track your symptoms and advocate for testing—don't wait for your doctor to connect the dots. Start mindfulness and journaling daily to help process changes and center yourself. Explore integrative therapies, such as acupuncture, dietary changes, and vaginal health supplements, to enhance quality of life.   Important Chapters & Timestamps00:00 – Intro & Meet Amita03:00 – From Architecture to High-Tech to Holistic Health07:00 – What Perimenopause Really Feels Like12:00 – Mental Health Impact: Depression, Anxiety & Fog16:00 – Cultural Stigma & Workplace Silence22:00 – Loss of Libido, Intimacy, and Sexual Health28:00 – How NourishDoc Empowers Women35:00 – Systemic Gaps in Women's Healthcare43:00 – Amita's Advice to Her Younger Self References: NourishDoc Research & Programs – http://www.nourishdoc.com/ WHO and NIH studies on menopause-related mental health PubMed clinical research (as referenced by Amita)   Subscribe, Rate, and Review!Love what you heard? Don't forget to subscribe for more bold, unfiltered stories about the real stuff going on in our heads. Please take a moment to rate & review us on your favorite podcast platform or on our website:https://goesoninourheads.net/add-your-podcast-reviews For feedback, stories, or shoutouts, visit:https://castfeedback.com/67521f0bde0b101c7b10442a #MentalHealthPodcast #MentalHealthAwareness #PerimenopauseSupport #MidlifeWomenWellness#MenopauseJourney #NourishDoc #AmitaSharma #Grex #DirtySkittles #MindfulnessHealing#HormoneHealth #WomenOver40 #HolisticMentalHealth #AnxietySupport #BurnoutRecovery#SelfCareTips #PodcastForWomen #ChronicConditionPrevention #Podmatch #HealthEquityForWomen ***************************************************************************If You Need Support, Reach OutIf you or someone you know is facing mental health challenges, please don't hesitate to reach out to a crisis hotline in your area. Remember, it's OK not to be OK—talking to someone can make all the difference.United States: Call or Text 988 — 988lifeline.orgCanada: Call or Text 988 — 988.caWorldwide: Find a HelplineMental Health Resources and Tools: The Help HubStay Connected with G-Rex and Dirty SkittlesOfficial Website: goesoninourheads.netFacebook: @shltthatgoesoninourheadsInstagram: @grex_and_dirtyskittlesLinkedIn: G-Rex and Dirty SkittlesJoin Our Newsletter: Sign Up HereMerch Store: goesoninourheads.shopAudio Editing by NJz Audio

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. BioNTech is focusing on infectious diseases as vaccine rates drop, with expectations that the US COVID-19 vaccination rate will decrease slightly. Glioblastoma research is seeing increased funding and interest from companies like Merck and Jazz Pharmaceuticals. The FDA's rejection of Replimmune's melanoma drug, despite staff consensus, has caused a drop in the company's stock. Sarepta and Capricor learned of regulatory decisions through media leaks, causing confusion for patients and families. Trilink Biotechnologies offers process development services for nucleic acid therapeutic development. Lotte Biologics is expanding globally, Allogene is discontinuing an immunosuppressive antibody after a patient death, and NIH funding cuts are impacting biotech. Pharmas are increasing investment in AI despite challenges in the industry. Trump urges pharma companies to address drug pricing, while Merck plans to cut 6,000 jobs to save $3 billion.

Dr. Elias Zerhouni's journey began in Algeria, where he taught himself mathematics as bombs fell outside his window. With two suitcases and a few hundred dollars, his family eventually immigrated to the United States. Driven by an unshakable belief in science and service, Zerhouni rose through the ranks of medical research to become director of the National Institutes of Health under President George W. Bush. In his new memoir, “Disease Knows No Politics,” he reflects on his personal journey and the fierce political battles he faced while leading the NIH. He joins us to discuss the vital contributions of immigrants to American innovation and the urgent need to safeguard science from partisanship. Guests: Dr. Elias Zerhouni, former director, National Institute of Health; professor emeritus, Johns Hopkins University Learn more about your ad choices. Visit megaphone.fm/adchoices

Kick off your week with Wake Up on the Live the Dream Media Network! 1st hour: Recap of our wonderful private dinner at Reforma. Dr. Marty Makary talks about the NIH cooking up the C19 virus plus how some Democrats seeing going full Communist is the way forward! 2nd hour: Mayor Jon Post of the Great Town of Marana in studio to talk about RTA and the latest updates in SoAZ's best town 3rd hour: Brother Joe DeSimone makes his weekly appearance to talk about the latest economic news and how it affects your retirement plans.

TWiV reports the administration putting a choke hold on billions of NIH health research funding, US Senators tell scientists they want to protect the NIH budget, then review a classic experiment showing the mechanism of DNA replication, and explain how jumbo phage DNA is transcribed in a membrane-bound compartment before transfer into proteinaceous “nucleus” compartment. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, Brianne Barker, Jolene Ramsey, and Angela Mingarelli Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV 5:13 Chokehold on billions in NIH funding (WSJ) Senators want to protect NIH budget (Nature) Replication of DNA in E. coli (PNAS) Biography of Franklin Stahl (DNA Learning Center) Franklin Stahl, 95 (Caltech Magazine) FW Stahl dies (NY Times) Requiem for a machine (Small Things Considered) Membrane and protein bound organelles during phage infection (Cell Host Micr) Letters read on TWiV 1241 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Angela – Benefits of interacting with Nature Brianne – “Why Trust Science” Essay Kathy – Dental floss delivery of vaccines to mice Rich – The Monk in the Garden Jolene – JWST COSMOS-Web Interactive Map viewer Vincent – New Injectable Recommended by Europe for HIV Prevention Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Welcome back to Snafu w/ Robin Zander.  In this episode, I'm joined by Brian Elliott, former Slack executive and co-founder of Future Forum. We discuss the common mistakes leaders make about AI and why trust and transparency are more crucial than ever. Brian shares lessons from building high-performing teams, what makes good leadership, and how to foster real collaboration. He also reflects on raising values-driven kids, the breakdown of institutional trust, and why purpose matters. We touch on the early research behind Future Forum and what he'd do differently today. Brian will also be joining us live at Responsive Conference 2025, and I'm excited to continue the conversation there. If you haven't gotten your tickets yet, get them here. What Do Most People Get Wrong About AI? (1:53) “Senior leaders sit on polar ends of the spectrum on this stuff. Very, very infrequently, sit in the middle, which is kind of where I find myself too often.”  Robin notes Brian will be co-leading an active session on AI at Responsive Conference with longtime collaborator Helen Kupp. He tees up the conversation by saying Brian holds “a lot of controversial opinions” on AI, not that it's insignificant, but that there's a lot of “idealization.” Brian says most senior leaders fall into one of two camps: Camp A: “Oh my God, this changes everything.” These are the fear-mongers shouting: “If you don't adopt now, your career is over.” Camp B: “This will blow over.” They treat AI as just another productivity fad, like others before it. Brian positions himself somewhere in the middle but is frustrated by both ends of the spectrum. He points out that the loudest voices (Mark Benioff, Andy Jassy, Zuckerberg, Sam Altman) are “arms merchants” – they're pushing AI tools because they've invested billions. These tools are massively expensive to build and run, and unless they displace labor, it's unclear how they generate ROI. believe in AI's potential and  aggressively push adoption inside their companies. So, naturally, these execs have to: But “nothing ever changes that fast,” and both the hype and the dismissal are off-base. Why Playing with AI Matters More Than Training (3:29) AI is materially different from past tech, but what's missing is attention to how adoption happens. “The organizational craft of driving adoption is not about handing out tools. It's all emotional.” Adoption depends on whether people respond with fear or aspiration, not whether they have the software. Frontline managers are key: it's their job to create the time and space for teams to experiment with AI. Brian credits Helen Kupp for being great at facilitating this kind of low-stakes experimentation. Suggests teams should “play with AI tools” in a way totally unrelated to their actual job. Example: take a look at your fridge, list the ingredients you have, and have AI suggest a recipe. “Well, that's a sucky recipe, but it could do that, right?” The point isn't utility,  it's comfort and conversation: What's OK to use AI for? Is it acceptable to draft your self-assessment for performance reviews with AI? Should you tell your boss or hide it? The Purpose of Doing the Thing (5:30) Robin brings up Ezra Klein's podcast in The New York Times, where Ezra asks: “What's the purpose of writing an essay in college?” AI can now do better research than a student, faster and maybe more accurately. But Robin argues that the act of writing is what matters, not just the output. Says: “I'm much better at writing that letter than ChatGPT can ever be, because only Robin Zander can write that letter.” Example: Robin and his partner are in contract on a house and wrote a letter to the seller – the usual “sob story” to win favor. All the writing he's done over the past two years prepared him to write that one letter better. “The utility of doing the thing is not the thing itself – it's what it trains.” Learning How to Learn (6:35) Robin's fascinated by “skills that train skills” – a lifelong theme in both work and athletics. He brings up Josh Waitzkin (from Searching for Bobby Fischer), who went from chess prodigy to big wave surfer to foil board rider. Josh trained his surfing skills by riding a OneWheel through NYC, practicing balance in a different context. Robin is drawn to that kind of transfer learning and “meta-learning” – especially since it's so hard to measure or study. He asks: What might AI be training in us that isn't the thing itself? We don't yet know the cognitive effects of using generative AI daily, but we should be asking. Cognitive Risk vs. Capability Boost (8:00) Brian brings up early research suggesting AI could make us “dumber.” Outsourcing thinking to AI reduces sharpness over time. But also: the “10,000 repetitions” idea still holds weight – doing the thing builds skill. There's a tension between “performance mode” (getting the thing done) and “growth mode” (learning). He relates it to writing: Says he's a decent writer, not a great one, but wants to keep getting better. Has a “quad project” with an editor who helps refine tone and clarity but doesn't do the writing. The setup: he provides 80% drafts, guidelines, tone notes, and past writing samples. The AI/editor cleans things up, but Brian still reviews: “I want that colloquialism back in.” “I want that specific example back in.” “That's clunky, I don't want to keep it.” Writing is iterative, and tools can help, but shouldn't replace his voice. On Em Dashes & Detecting Human Writing (9:30) Robin shares a trick: he used em dashes long before ChatGPT and does them with a space on either side. He says that ChatGPT's em dashes are double-length and don't have spaces. If you want to prove ChatGPT didn't write something, “just add the space.” Brian agrees and jokes that his editors often remove the spaces, but he puts them back in. Reiterates that professional human editors like the ones he works with at Charter and Sloan are still better than AI. Closing the Gap Takes More Than Practice (10:31) Robin references The Gap by Ira Glass, a 2014 video that explores the disconnect between a creator's vision and their current ability to execute on that vision. He highlights Glass's core advice: the only way to close that gap is through consistent repetition – what Glass calls “the reps.” Brian agrees, noting that putting in the reps is exactly what creators must do, even when their output doesn't yet meet their standards. Brian also brings up his recent conversation with Nick Petrie, whose work focuses not only on what causes burnout but also on what actually resolves it. He notes research showing that people stuck in repetitive performance mode – like doctors doing the same task for decades – eventually see a decline in performance. Brian recommends mixing in growth opportunities alongside mastery work. “exploit” mode (doing what you're already good at) and  “explore” mode (trying something new that pushes you) He says doing things that stretch your boundaries builds muscle that strengthens your core skills and breaks stagnation. He emphasizes the value of alternating between  He adds that this applies just as much to personal growth, especially when people begin to question their deeper purpose and ask hard questions like, “Is this all there is to my life or career? Brian observes that stepping back for self-reflection is often necessary, either by choice or because burnout forces a hard stop. He suggests that sustainable performance requires not just consistency but also intentional space for growth, purpose, and honest self-evaluation. Why Taste And Soft Skills Now Matter More Than Ever (12:30) On AI, Brian argues that most people get it wrong. “I do think it's augmentation.” The tools are evolving rapidly, and so are the ways we use them. They view it as a way to speed up work, especially for engineers, but that's missing the bigger picture. Brian stresses that EQ is becoming more important than IQ. Companies still need people with developer mindsets – hypothesis-driven, structured thinkers. But now, communication, empathy, and adaptability are no longer optional; they are critical. “Human communication skills just went from ‘they kind of suck at it but it's okay' to ‘that's not acceptable.'” As AI takes over more specialist tasks, the value of generalists is rising. People who can generate ideas, anticipate consequences, and rally others around a vision will be most valuable. “Tools can handle the specialized knowledge – but only humans can connect it to purpose.” Brian warns that traditional job descriptions and org charts are becoming obsolete. Instead of looking for ways to rush employees into doing more work, “rethink the roles. What can a small group do when aligned around a common purpose?” The future lies in small, aligned teams with shared goals. Vision Is Not a Strategy (15:56) Robin reflects on durable human traits through Steve Jobs' bio by Isaac Walterson. Jobs succeeded not just with tech, but with taste, persuasion, charisma, and vision. “He was less technologist, more storyteller.” They discuss Sam Altman, the subject of Empire of AI. Whether or not the book is fully accurate, Robin argues that Altman's defining trait is deal-making. Robin shares his experience using ChatGPT in real estate. It changed how he researched topics like redwood root systems on foundational structure and mosquito mitigation. Despite the tech, both agree that human connection is more important than ever. “We need humans now more than ever.” Brian references data from Kelly Monahan showing AI power users are highly productive but deeply burned out. 40% more productive than their peers. 88% are completely burnt out. Many don't believe their company's AI strategy, even while using the tools daily. There's a growing disconnect between executive AI hype and on-the-ground experience. But internal tests by top engineers showed only 10% improvement, mostly in simple tasks. “You've got to get into the tools yourself to be fluent on this.” One CTO believed AI would produce 30% efficiency gains. Brian urges leaders to personally engage with the tools before making sweeping decisions. He warns against blindly accepting optimistic vendor promises or trends. Leaders pushing AI without firsthand experience risk overburdening their teams. “You're bringing the Kool-Aid and then you're shoving it down your team's throat.” This results in burnout, not productivity. “You're cranking up the demands. You're cranking up the burnout, too.” “That's not going to lead to what you want either.” If You Want Control, Just Say That (20:47) Robin raises the topic of returning to the office, which has been a long-standing area of interest for him. “I interviewed Joel Gascoyne on stage in 2016… the largest fully distributed company in the world at the time.” He's tracked distributed work since Responsive 2016. Also mentions Shelby Wolpa (ex-Envision), who scaled thousands remotely. Robin notes the shift post-COVID: companies are mandating returns without adjusting for today's realities.” Example: “Intel just did a mandatory 4 days a week return to office… and now people live hours away.” He acknowledges the benefits of in-person collaboration, especially in creative or physical industries. “There is an undeniable utility.”, especially as they met in Robin's Cafe to talk about Responsive, despite a commute, because it was worth it. But he challenges blanket return-to-office mandates, especially when the rationale is unclear. According to Brian, any company uses RTO as a veiled soft layoff tactic. Cites Elon Musk and Vivek Ramaswamy openly stating RTO is meant to encourage attrition. He says policies without clarity are ineffective. “If you quit, I don't have to pay you severance.” Robin notes that the Responsive Manifesto isn't about providing answers but outlining tensions to balance. Before enforcing an RTO policy, leaders should ask: “What problem are we trying to solve – and do we have evidence of it?” Before You Mandate, Check the Data (24:50) Performance data should guide decisions, not executive assumptions. For instance, junior salespeople may benefit from in-person mentorship, but… That may only apply to certain teams, and doesn't justify full mandates. “I've seen situations where productivity has fallen – well-defined productivity.” The decision-making process should be decentralized and nuanced. Different teams have different needs — orgs must avoid one-size-fits-all policies, especially in large, distributed orgs. “Should your CEO be making that decision? Or should your head of sales?” Brian offers a two-part test for leaders to assess their RTO logic: Are you trying to attract and retain the best talent? Are your teams co-located or distributed? If the answer to #1 is yes: People will be less engaged, not more. High performers will quietly leave or disengage while staying. Forcing long commutes will hurt retention and morale. If the answer to #2 is “distributed”: Brian then tells a story about a JPMorgan IT manager who asks Jamie Dimon for flexibility. “It's freaking stupid… it actually made it harder to do their core work.” Instead, teams need to define shared norms and operating agreements. “Teams have to have norms to be effective.” RTO makes even less sense. His team spanned time zones and offices, forcing them into daily hurt collaboration. He argues most RTO mandates are driven by fear and a desire for control. More important than office days are questions like: What hours are we available for meetings? What tools do we use and why? How do we make decisions? Who owns which roles and responsibilities? The Bottom Line: The policy must match the structure. If teams are remote by design, dragging them into an office is counterproductive. How to Be a Leader in Chaotic Times (28:34) “We're living in a more chaotic time than any in my lifetime.” Robin asks how leaders should guide their organizations through uncertainty. He reflects on his early work years during the 2008 crash and the unpredictability he's seen since. Observes current instability like the UCSF and NIH funding and hiring freezes disrupting universities, rising political violence, and murders of public officials from the McKnight Foundation, and more may persist for years without relief. “I was bussing tables for two weeks, quit, became a personal trainer… my old client jumped out a window because he lost his fortune as a banker.” Brian says what's needed now is: Resilience – a mindset of positive realism: acknowledging the issues, while focusing on agency and possibility, and supporting one another. Trust – not just psychological safety, but deep belief in leadership clarity and honesty. His definition of resilience includes: “What options do we have?” “What can we do as a team?” “What's the opportunity in this?” What Builds Trust (and What Breaks It) (31:00) Brian recalls laying off more people than he hired during the dot-com bust – and what helped his team endure: “Here's what we need to do. If you're all in, we'll get through this together.” He believes trust is built when: Leaders communicate clearly and early. They acknowledge difficulty, without sugarcoating. They create clarity about what matters most right now. They involve their team in solutions. He critiques companies that delay communication until they're in PR cleanup mode: Like Target's CEO, who responded to backlash months too late – and with vague platitudes. “Of course, he got backlash,” Brian says. “He wasn't present.” According to him, “Trust isn't just psychological safety. It's also honesty.” Trust Makes Work Faster, Better, and More Fun (34:10) “When trust is there, the work is more fun, and the results are better.” Robin offers a Zander Media story: Longtime collaborator Jonathan Kofahl lives in Austin. Despite being remote, they prep for shoots with 3-minute calls instead of hour-long meetings. The relationship is fast, fluid, and joyful, and the end product reflects that. He explains the ripple effects of trust: Faster workflows Higher-quality output More fun and less burnout Better client experience Fewer miscommunications or dropped balls He also likens it to acrobatics: “If trust isn't there, you land on your head.” Seldom Wrong, Never in Doubt (35:45) “Seldom wrong, never in doubt – that bit me in the butt.” Brian reflects on a toxic early-career mantra: As a young consultant, he was taught to project confidence at all times. It was said that “if you show doubt, you lose credibility,” especially with older clients. Why that backfired: It made him arrogant. It discouraged honest questions or collaborative problem-solving. It modeled bad leadership for others. Brian critiques the startup world's hero culture: Tech glorifies mavericks and contrarians, people who bet against the grain and win. But we rarely see the 95% who bet big and failed, and the survivors become models, often with toxic effects. The real danger: Leaders try to imitate success without understanding the context. Contrarianism becomes a virtue in itself – even when it's wrong. Now, he models something else: “I can point to the mountain, but I don't know the exact path.” Leaders should admit they don't have all the answers. Inviting the team to figure it out together builds alignment and ownership. That's how you lead through uncertainty, by trusting your team to co-create. Slack, Remote Work, and the Birth of Future Forum (37:40) Brian recalls the early days of Future Forum: Slack was deeply office-centric pre-pandemic. He worked 5 days a week in SF, and even interns were expected to show up regularly. Slack's leadership, especially CTO Cal Henderson, was hesitant to go remote, not because they were anti-remote, but because they didn't know how. But when COVID hit, Slack, like everyone else, had to figure out remote work in real time. Brian had long-standing relationships with Slack's internal research team: He pitched Stewart Butterfield (Slack's CEO) on the idea of a think tank, where he was then joined by Helen Kupp and Sheela Subramanian, who became his co-founders in the venture. Thus, Future Forum was born. Christina Janzer, Lucas Puente, and others. Their research was excellent, but mostly internal-facing, used for product and marketing. Brian, self-described as a “data geek,” saw an opportunity: Remote Work Increased Belonging, But Not for Everyone (40:56) In mid-2020, Future Forum launched its first major study. Expected finding: employee belonging would drop due to isolation. Reality: it did, but not equally across all demographics. For Black office workers, a sense of belonging actually increased. Future Forum brought in Dr. Brian Lowery, a Black professor at Stanford, to help interpret the results. Lowery explained: “I'm a Black professor at Stanford. Whatever you think of it as a liberal school, if I have to walk on that campus five days a week and be on and not be Black five days a week, 9 to 5 – it's taxing. It's exhausting. If I can dial in and out of that situation, it's a release.” A Philosophy Disguised as a Playbook (42:00) Brian, Helen, and Sheela co-authored a book that distilled lessons from: Slack's research Hundreds of executive conversations Real-world trials during the remote work shift One editor even commented on how the book is “more like a philosophy book disguised as a playbook.” The key principles are: “Start with what matters to us as an organization. Then ask: What's safe to try?” Policies don't work. Principles do. Norms > mandates. Team-level agreements matter more than companywide rules. Focus on outcomes, not activity.  Train your managers. Clarity, trust, and support start there. Safe-to-try experiments. Iterate fast and test what works for your team. Co-create team norms. Define how decisions get made, what tools get used, and when people are available. What's great with the book is that no matter where you are, this same set of rules still applies.  When Leadership Means Letting Go (43:54) “My job was to model the kind of presence I wanted my team to show.” Robin recalls a defining moment at Robin's Café: Employees were chatting behind the counter while a banana peel sat on the floor, surrounded by dirty dishes. It was a lawsuit waiting to happen. His first impulse was to berate them, a habit from his small business upbringing. But in that moment, he reframed his role. “I'm here to inspire, model, and demonstrate the behavior I want to see.” He realized: Hovering behind the counter = surveillance, not leadership. True leadership = empowering your team to care, even when you're not around. You train your manager to create a culture, not compliance. Brian and Robin agree: Rules only go so far. Teams thrive when they believe in the ‘why' behind the work. Robin draws a link between strong workplace culture and… The global rise of authoritarianism The erosion of trust in institutions If trust makes Zander Media better, and helps VC-backed companies scale — “Why do our political systems seem to be rewarding the exact opposite?” Populism, Charisma & Bullshit (45:20) According to Robin, “We're in a world where trust is in very short supply.” Brian reflects on why authoritarianism is thriving globally: The media is fragmented. Everyone's in different pocket universes. People now get news from YouTube or TikTok, not trusted institutions. Truth is no longer shared, and without shared truth, trust collapses. “Walter Cronkite doesn't exist anymore.” He references Andor, where the character, Mon Mothma, says: People no longer trust journalism, government, universities, science, or even business. Edelman's Trust Barometer dipped for business leaders for the first time in 25 years. CEOs who once declared strong values are now going silent, which damages trust even more. “The death of truth is really the problem that's at work here.” Robin points out: Trump and Elon, both charismatic, populist figures, continue to gain power despite low trust. Why? Because their clarity and simplicity still outperform thoughtful leadership. He also calls Trump a “marketing genius.” Brian's frustration: Case in point: Trump-era officials who spread conspiracy theories now can't walk them back. Populists manufacture distrust, then struggle to govern once in power. He shares a recent example: Result: Their base turned on them. Right-wing pundits (Pam Bondi, Dan Bongino) fanned Jeffrey Epstein conspiracies. But in power, they had to admit: “There's no client list publicly.” Brian then suggests that trust should be rebuilt locally. He points to leaders like Zohran Mamdani (NY): “I may not agree with all his positions, but he can articulate a populist vision that isn't exploitative.” Where Are the Leaders? (51:19) Brian expresses frustration at the silence from people in power: “I'm disappointed, highly disappointed, in the number of leaders in positions of power and authority who could lend their voice to something as basic as: science is real.” He calls for a return to shared facts: “Let's just start with: vaccines do not cause autism. Let's start there.” He draws a line between public health and trust: We've had over a century of scientific evidence backing vaccines But misinformation is eroding communal health Brian clarifies: this isn't about wedge issues like guns or Roe v. Wade The problem is that scientists lack public authority, but CEOs don't CEOs of major institutions could shift the narrative, especially those with massive employee bases. And yet, most say nothing: “They know it's going to bite them… and still, no one's saying it.” He warns: ignoring this will hurt businesses, frontline workers, and society at large. 89 Seconds from Midnight (52:45) Robin brings up the Doomsday Clock: Historically, it was 2–4 minutes to midnight “We are 89 seconds to midnight.” (as of January 2025) This was issued by the Bulletin of Atomic Scientists, a symbol of how close humanity is to destroying itself. Despite that, he remains hopeful: “I might be the most energetic person in any room – and yet, I'm a prepper.” Robin shared that: And in a real emergency? You might not make it. He grew up in the wilderness, where ambulances don't arrive, and CPR is a ritual of death. He frequently visits Vieques, an island off Puerto Rico with no hospital, where a car crash likely means you won't survive. As there is a saying there that goes, ‘No Hay Hospital', meaning ‘there is no hospital'. If something serious happens, you're likely a few hours' drive or even a flight away from medical care. That shapes his worldview: “We've forgotten how precious life is in privileged countries.” Despite his joy and optimism, Robin is also: Deeply aware of fragility – of systems, bodies, institutions. Committed to preparation, not paranoia. Focused on teaching resilience, care, and responsibility. How to Raise Men with Heart and Backbone (55:00) Robin asks: “How do you counsel your boys to show up as protectors and earners, especially in a capitalist world, while also taking care of people, especially when we're facing the potential end of humanity in our lifetimes?” Brian responds: His sons are now 25 and 23, and he's incredibly proud of who they're becoming. Credits both parenting and luck but he also acknowledges many friends who've had harder parenting experiences. His sons are: Sharp and thoughtful In healthy relationships Focused on values over achievements Educational path: “They think deeply about what are now called ‘social justice' issues in a very real way.” Example: In 4th grade, their class did a homelessness simulation – replicating the fragmented, frustrating process of accessing services. Preschool at the Jewish Community Center Elementary at a Quaker school in San Francisco He jokes that they needed a Buddhist high school to complete the loop Not religious, but values-based, non-dogmatic education had a real impact That hands-on empathy helped them see systemic problems early on, especially in San Francisco, where it's worse. What Is Actually Enough? (56:54) “We were terrified our kids would take their comfort for granted.” Brian's kids: Lived modestly, but comfortably in San Francisco. Took vacations, had more than he and his wife did growing up. Worried their sons would chase status over substance. But what he taught them instead: Family matters. Friendships matter. Being dependable matters. Not just being good, but being someone others can count on. He also cautioned against: “We too often push kids toward something unattainable, and we act surprised when they burn out in the pursuit of that.” The “gold ring” mentality is like chasing elite schools, careers, and accolades. In sports and academics, he and his wife aimed for balance, not obsession. Brian on Parenting, Purpose, and Perspective (59:15) Brian sees promise in his kids' generation: But also more: Purpose-driven Skeptical of false promises Less obsessed with traditional success markers Yes, they're more stressed and overamped on social media. Gen Z has been labeled just like every generation before: “I'm Gen X. They literally made a movie about us called Slackers.” He believes the best thing we can do is: Model what matters Spend time reflecting: What really does matter? Help the next generation define enough for themselves, earlier than we did. The Real Measure of Success (1:00:07) Brian references Clay Christensen, famed author of The Innovator's Dilemma and How Will You Measure Your Life? Clay's insight: “Success isn't what you thought it was.” Early reunions are full of bravado – titles, accomplishments, money. Later reunions reveal divorce, estrangement, and regret. The longer you go, the more you see: Brian's takeaway: Even for Elon, it might be about Mars. But for most of us, it's not about how many projects we shipped. It's about: Family Friends Presence Meaning “If you can realize that earlier, you give yourself the chance to adjust – and find your way back.” Where to Find Brian (01:02:05) LinkedIn WorkForward.com Newsletter: The Work Forward on Substack “Some weeks it's lame, some weeks it's great. But there's a lot of community and feedback.” And of course, join us at Responsive Conference this September 17-18, 2025. Books Mentioned How Will You Measure Your Life? by Clayton Christensen The Innovator's Dilemma by Clayton Christensen Responsive Manifesto Empire of AI by Karen Hao Podcasts Mentioned The Gap by Ira Glass The Ezra Klein Show Movies Mentioned Andor Slackers Organizations Mentioned: Bulletin of Atomic Scientists McKnight Foundation National Institutes of Health (NIH) Responsive.org University of California, San Francisco

Former NIH director Elias Zerhouni reflects on the agency's triumphs and shortcomings in light of his new memoir, Disease Knows No Politics. He defends the NIH's legacy while addressing critiques from figures like current NIH head Jay Bhattacharya, and warns that proposed funding cuts could severely undermine scientific progress. Also: the decline of late-night TV amid political sameness, the comic potential of Sydney Sweeney's controversial jeans ad, and a failed auction bid for Larry King's designer denim. Produced by Corey Wara Production Coordinator Ashley Khan Email us at ⁠⁠⁠⁠thegist@mikepesca.com⁠⁠⁠⁠ To advertise on the show, contact ⁠⁠⁠⁠ad-sales@libsyn.com⁠⁠⁠⁠ or visit ⁠⁠⁠⁠https://advertising.libsyn.com/TheGist⁠⁠⁠⁠ Subscribe to The Gist: ⁠⁠⁠⁠https://subscribe.mikepesca.com/⁠⁠⁠⁠ Subscribe to The Gist Youtube Page: ⁠⁠⁠⁠https://www.youtube.com/channel/UC4_bh0wHgk2YfpKf4rg40_g⁠⁠⁠⁠ Subscribe to The Gist Instagram Page: ⁠⁠⁠⁠GIST INSTAGRAM⁠⁠⁠⁠ Follow The Gist List at: ⁠⁠⁠⁠Pesca⁠⁠⁠⁠ ⁠⁠⁠⁠Profundities | Mike Pesca | Substack⁠⁠⁠⁠

U.S. biopharma clusters are responding to high interest rates, NIH restructuring, and FDA changes while maintaining investment in research and development. Boston/Cambridge, San Francisco Bay Area, BioHealth Capital Region, New York/New Jersey, San Diego, Los Angeles/Orange County, Greater Philadelphia, North Carolina, Seattle, and Chicagoland rank as the top ten regions based on patents, NIH funding, venture capital, laboratory space, and jobs. Major projects, mergers, and facility expansions are underway in these regions, with efforts focused on addressing unmet medical needs, supporting domestic drug manufacturing, and advancing biotechnology for national security and economic growth.Learn more on this news by visiting us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.

Howie and Harlan discuss Dr. Vinay Prasad's departure from the FDA after a backlash against his decisions on Sarepta's Duchenne muscular dystrophy gene therapy. Also examined: AI in clinical settings, changes in NIH grantmaking, and the 60th anniversary of Medicare and Medicaid. Links: Sarepta and the FDA “STAT breaks down the confusing, heartbreaking Sarepta saga” “Sarepta Therapeutics' Duchenne therapy faces ‘arduous' path back to market, senior FDA official says” “For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak” “FDA launches probe into new Elevidys death as Sarepta, Roche stress gene therapy not at fault” “FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients” “FDA takes U-turn on Sarepta's Elevidys, backing Duchenne gene therapy again in ambulatory patients” “Controversial FDA official Dr. Vinay Prasad departs agency” “Top F.D.A. Vaccine Official Resigns, Citing Kennedy's ‘Misinformation and Lies'” “Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag” “Timeline: The Rise and Fall of Vioxx” “What have we learnt from Vioxx?” THC in pizza dough “C.D.C. Ties 85 Cases of THC-Related Symptoms to Wisconsin Restaurant” “Tetrahydrocannabinol Intoxication from Food at a Restaurant — Wisconsin, October 2024” NIH funding “NIH is shrinking the number of research projects it funds due to a new Trump policy” NIH: Supporting Fairness and Originality in NIH Research Applications “Fearful of AI-generated grant proposals, NIH limits scientists to six applications per year” “Trump budget draft proposes NIH consolidation and 40% spending cut” Raw milk “Outbreak of Salmonella Typhimurium Infections Linked to Commercially Distributed Raw Milk — California and Four Other States, September 2023–March 2024” “The Dangers of Raw Milk: Unpasteurized Milk Can Pose a Serious Health Risk” AI in healthcare update “Ambience Healthcare Announces $243 Million Series C to Scale its AI Platform for Health Systems” “As ambient scribes face off, Doximity lures doctors with a free option” Aidoc: “AI Empowering Radiologists” “Clinical Implementation of a Combined Artificial Intelligence and Natural Language Processing Quality Assurance Program for Pulmonary Nodule Detection in the Emergency Department Setting” “Large Language Models as an Inexpensive and Effective Extra Set of Eyes in Radiology Reporting” “Current Trends in Remote and Flexible Work Options in Radiology and Perception of Impact on Radiologist Well-being” Medicare and Medicaid 60th anniversary CMS' program history “Medicare and Medicaid turn 60 – and face historic cuts decades in the making” UnitedHealth and Medicare Advantage “UnitedHealth says 2025 earnings will be worse than expected as high medical costs dog insurers” “UnitedHealthcare to exit certain Medicare Advantage markets as costs balloon, impacting 600K enrollees” “Novo Nordisk slides further on US competition, new CEO concerns” “Dems Must Really Fix Medicaid, Not Just Undo Trump's Damage to It”   Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

My fellow pro-growth/progress/abundance Up Wingers,The innovation landscape is facing a difficult paradox: Even as R&D investment has increased, productivity per dollar invested is in decline. In his recent co-authored paper, The next innovation revolution—powered by AI, Michael Chui explores AI as a possible solution to this dilemma.Today on Faster, Please! — The Podcast, Chui and I explore the vast potential for AI-augmented research and the challenges and opportunities that come with applying it to the real-world.Chui is a senior fellow at QuantumBlack, McKinsey's AI unit, where he leads McKinsey research in AI, automation, and the future of work.In This Episode* The R&D productivity problem (01:21)* The AI solution (6:13)* The business-adoption bottleneck (11:55)* The man-machine team (18:06)* Are we ready? (19:33)Below is a lightly edited transcript of our conversation. The R&D productivity problem (01:21)All the easy stuff, we already figured out. So the low-hanging fruit has been picked, things are getting harder and harder.Pethokoukis: Do we understand what explains this phenomenon where we seem to be doing lots of science, and we're spending lots of money on R&D, but the actual productivity of that R&D is declining? Do we have a good explanation for that?I don't know if we have just one good explanation. The folks that we both know have been both working on what are the causes of this, as well as what are some of the potential solutions, but I think it's a bit of a hidden problem. I don't think everyone understands that there are a set of people who have looked at this — quite notably Nick Bloom at Stanford who published this somewhat famous paper that some people are familiar with. But it is surprising in some sense.At one level, it's amazing what science and engineering has been able to do. We continue to see these incredible advances, whether it's in AI, or biotechnology, or whatever; but also, what Nick and other researchers have discovered is that we are producing less for every dollar we spend in R&D. That's this little bit of a paradox, or this challenge, that we see. What some of the research we've been trying to do is understand, can AI try to contribute to bending those curves?. . . I'm a computer scientist by training. I love this idea of Moore's Law: Every couple of years you can double the number of transistors you can put on a chip, or whatever, for the same amount of money. There's something called “Eroom's Law,” which is Moore spelled backwards, and basically it said: For decades in the pharmaceutical industry, the number of compounds or drugs you would produce for every billion dollars of R&D would get cut in half every nine years. That's obviously moving in the wrong direction. That challenge, I don't think everyone is aware of, but one that we need to address.I suppose, in a way, it does make sense that as we tackle harder problems, and we climb the tree of knowledge, that it's going to take more time, maybe more researchers, the researchers themselves may have to spend more time in school, so it may be a bit of a hidden problem, but it makes some intuitive sense to me.I think there's a way to think about it that way, which is: All the easy stuff, we already figured out. So the low-hanging fruit has been picked, things are getting harder and harder. It's amazing. You could look at some of the early papers in any field and it have a handful of authors, right? The DNA paper, three authors — although it probably should have included Rosalyn Franklin . . . Now you look at a physics paper or a computer science paper — the author list just goes on sometimes for pages. These problems are harder. They require more and more effort, whether it's people's talents, or whether it's computing power, or large-scale experiments, things are getting harder to do. I think there's ways in which that makes sense. Are there other ways in which we could improve processes? Probably, too.We could invest more in research, make it more efficient, and encourage more people to become researchers. To me, what's more exciting than automating different customer service processes is accelerating scientific discovery. I think that's what makes AI so compelling.That is exactly right. Now, by the way, I think we need to continue to invest in basic research and in science and engineering, I think that's absolutely important, but —That's worth noting, because I'm not sure everybody thinks that, so I'm glad you highlighted that.I don't think AI means that everything becomes cheaper and we don't need to invest in both human talent as well as in research. That's number one.Number two, as you said, we spend a lot of time, and appropriately so, talking about how AI can improve productivity, make things more efficient, do the things that we do already cheaper and faster. I think that's absolutely true. But we had the opportunity to look over history, and what has actually improved the human condition, what has been one of the things that has been necessary to improve the human condition over decades, and centuries, and millennia, is, in fact, discovering new ideas, having scientific breakthroughs, turning those scientific breakthroughs into engineering that turn into products and services, that do everything from expand our lifespans to be able to provide us with food, more energy. All those sorts of things require innovation, require R&D, and what we've discovered is the potential for AI, not only to make things more efficient, but to produce more innovation, more ideas that hopefully will lead to breakthroughs that help us all.The AI solution (6:13)I think that's one of the other potentials of using AI, that it could both absorb some of the experience that people have, as well as stretch the bounds of what might be possible.I've heard described as an “IMI,” it's an invention that makes more invention. It's an invention of a method of invention. That sounds great — how's it going to do that?There are a couple of ways. We looked at three different channels through which AI could improve this process of innovation and R&D. The first one is just increasing the volume, velocity, and variety of different candidates. One way you could think about innovation is you create a whole bunch of candidates and then you filter them down to the ones that might be most effective. Number one, you can just fill that funnel faster, better, and with greater variety. That's number one.The candidates could be a molecule, it could be a drug, it could be a new alloy, it could be lots of things.Absolutely, or a design for a physical product. One of the interesting things is, this quote-unquote “modern AI” — AI's been around for 70 years — is based on foundation models, these large artificial neural networks trained on huge amounts of data, and they produce unstructured outputs. In many cases, language, we talk about LLMs.The interesting thing is, you can train these foundation models not just to generate language, but you can generate a protein, or a drug candidate, as you were saying. You can imagine the prompt being, “Please produce 10 drug candidates that address this condition, but without the following side effects.” That's not exactly how it works, but roughly speaking, that's the potential to generate these things, or generate an electrical circuit, or a design for an air foil or an airframe that has these characteristics. Being able to just generate those.The interesting thing is, not only can you generate them faster, but there's this idea that you can create more variety. We're usefully proud as humans about our creativity, but also, that judgment or that training that we have, that experience sometimes constrains it. The famous example was some folks created this machine called AlphaGo which was meant to compete against the world champion in this game called Go, a very complex strategic game. Famously, it beat the world champion, but one of the things it did is this famous Move 37, this move that everyone who was an expert at Go said, “That is nuts. Why would you possibly do that?” Because the machine was a little bit more unconstrained, actually came up with what you might describe as a creative idea. I think that's one of the other potentials of using AI, that it could both absorb some of the experience that people have, as well as stretch the bounds of what might be possible.So you come up with the design, and then a variety of options, and then AI can help model and test them.Exactly. So you generate a broader and more voluminous set of potential designs, candidates, whether it's molecules, or chemicals, or what have you. Now you need to narrow that down. Traditionally you would narrow it down either one, through physical testing — so put something into a wind tunnel or run it through the water if you're looking at a boat design, or something like that, or put it in an electromagnetic chamber and see how the antenna operates. You'd either test it physically, and then, of course, lots of people figured out how to use physics, mathematical equations, in order to create “digital twins.” So you have these long acronyms like CFD for computational fluid dynamics, basically a virtual wind tunnel, or what have you. Or you have finite element analysis, another way to model how a structure might perform, or computational electromagnetic modeling. All these ways that you can use physics to simulate things, and that's been terrific.But some of those models actually take hours, sometimes days, to run these models. It might be faster than building the physical prototype and then modeling it — again, sometimes you just wait until something breaks, you're doing failure testing. Then you could do that in a computer using these models. But sometimes they take a really long time, and one of the really interesting discoveries in “AI” is you can use that same neural network that we've used to simulate cognition or intelligence, but now you use it to simulate physical systems. So in some ways it's not AI, because you're not creating an artificial intelligence, you're creating an artificial wind tunnel. It's just a different way to model physics. Sometimes these problems get even more complicated . . . If you're trying to put an antenna on an airplane, you need to know how the airflow is going to go over it, but you need to know whether or not the radio frequency stuff works out too, all that RF stuff.So these multiphysics models, the complexity is even higher, and you can train these neural nets . . . even faster than these physics-based models. So we have these things called AI surrogate models. They're sort of surrogates. It's two steps removed, in some ways, from actual physical testing . . . Literally we've seen models that can run in minutes rather than hours, or an hour rather than a few days. That can accelerate things. We see this in weather forecasting in a number of different ways in which this can happen. If you can generate more candidates and then test them faster, you can imagine the whole R&D process really accelerating.The business-adoption bottleneck (11:55)We know that companies are using AI surrogates, deep learning surrogates, already, but is it being applied as many places as possible? No, it isn't.Does achieving your estimated productivity increases depend more on further technological advances or does it depend more on how companies adopt and implement the technology? Is the bottleneck still in the tech itself, or is it more about business adaptation?Mostly number two. The technology is going to continue to advance. As a technologist, I love all that stuff, but as usual, a lot of the challenges here are organizational challenges. We know that companies are using AI surrogates, deep learning surrogates, already, but is it being applied as many places as possible? No, it isn't. A lot of these things are organizational. Does it match your strategy, for instance? Do you have the right talent and organization in place?Let me just give one very specific example. In a lot of R&D organizations we know, there's a separate organization for physical testing and a separate organization for simulations. Simulation, in many cases, us physics-based, but you add these deep-learning surrogates as well. That doesn't make sense at some level. I'm not saying physical testing goes away, but you need to figure out when you should physically test, when you should use which simulation methods, when you should use deep-learning surrogates or AI techniques, et cetera, and that's just one organizational difference that you could make if you were in an organization that was actually taking this whole testing regime seriously, where you're actually parsing out when the optimal amount of physical testing is versus simulation, et cetera. There's a number of things where that's true.Even before AI, historically, there was a gap between novel, new technologies, what they can do in lab settings, and then how they're applied in real-world research or in business environments. That gap, I would guess, probably requires companies to rewire how they operate, which takes time.It is indeed, and it's funny that you use the word “rewiring.” My colleagues wrote a book entitled Rewired, which literally is about the different ways, together, that you need to, as you say, rewire or change the way an organization operates. Only one of those six chapters is around the tech stack. It's still absolutely important. You've got to get all that stuff right. But it is mostly all of the other things surrounding how you change and what organization operates in order to bring the full value of this together to reach scale.We also talk about pilot purgatory: “We did this cool experiment . . .” but when is it good enough that the CFOs talks about it at the quarterly earnings report? That requires the organization to change the way it operates. That's the learning we've seen all the time.We've been serving thousands of executives on their use of AI for seven years now. Nearly 80 percent of organizations say they're regularly using AI someplace in the business, but in a separate survey, only one percent say they're mature in that usage. There's this giant gap between just using AI and then actually having the value be created. And by the way, organizations that are creating that value are accelerating their performance difference. If you have a much more productive R&D organization that churns out products that are successful in the market, you're going to be ahead of your competitors, and that's what we're seeing too.Is there a specific problem that comes up over and over again with companies, either in their implementation of AI, maybe they don't trust it, they may not know how to use it? What do you think is the problem?Unfortunately, I don't think there's just one thing. My colleagues who do this work on Rewired, for instance — you kind of have to do all those things. You do have to have the right talent and organization in place. You have to figure out scaling, for instance. You have to figure out change management. All of those things together are what underpins outsized performance, so all those things have to be done.So if companies are successful, what is the productivity impact you see? We're talking about basically the current technology level, give or take. We're not talking about human-level AI, superintelligence, we're talking about AI more or less as it exists today. Everybody wants to accelerate productivity: governments around the world, companies. So give me a feel for that.There are different measures of productivity, but here what we're talking about is basically: How many new products, successful products, can you put out in the market? Our modeling says, depending on your industry, you could double your productivity, in other words, of R&D. In other words, you could put out double the amount of products and services — new products and services — that you have been previously.Now, that's not true for every industry. By the way, the impact of that is different for different industries because for some industries you are dependent — In pharmaceuticals, the majority of your value comes from producing new products and services over time because eventually the patent runs out or whatever. There are other industries, we talk about science-based industries like chemicals, for instance. The new-product development process in chemicals is very, very close to the science of chemistry. So these levers that I just talked about — producing more candidates, being able to evaluate them more quickly, and all the other things that LLMs can do, in general, we could see potential doubling in the pace of which innovation happens.On the other hand, the chemicals industry — let's leave out specialty chemicals, but the commodity chemicals — they'll still produce ethylene, right? So to a certain extent, while the R&D process can be accelerated a great deal, the EBIT [Earnings Before Interest and Taxes] impact on the industry might be lower than it is for pharmaceuticals, for instance. But still, it's valuable. And then, again, if you're in specialty chem, it means a lot to you. So depending on where you sit in your position in the market, it can vary, but the potential is really high.The man-machine team (18:06)At least for the medium term, we're not going to be able to get rid of all the people. The people are going to be absolutely important to the process.Will future R&D look more like researchers augmented by AI or AI systems assisted by researchers? Who's the assistant in this equation? Who's working for who?It's “all of the above” and it depends on how you decide to use these technologies, but we even write in our paper that we need to be thoughtful about where you put the human in the loop. Every study, the conditions matter, but there are lots of studies where you say, look, the combination of machines and humans — so AI and researchers — is the most powerful combination. Each brings their respective strengths to it, but the funny thing is that sometimes the human biases actually decrease the performance of the overall system, and so, oh, maybe we should just go with machines. At least for the medium term, we're not going to be able to get rid of all the people. The people are going to be absolutely important to the process.When is it that people either are necessary to the process or can be helpful? In many cases, it is around things like, when is it that you need to make a decision that's a safety-critical decision, a regulatory decision where you just have to have a person look at it? That's the sort of necessity argument for people in the loop. But also, there are things that machines just don't do well enough yet, and there's a little bit of that.Are we ready? (19:33). . . AI is one of those things that can produce potentially more of those ideas that can underpin, hopefully, an improved quality of life for us and our children.If we can get more productive R&D, and then businesses get better at incorporating this into their processes and they could potentially generate more products and services, do we have a government ready for that world of accelerated R&D? Can we handle that flow? My bias says probably not, but please correct me if I'm wrong.I think one of the interesting things is people talk about AI regulation. In many of these industries, the regulations already exist. We have regulations for what goes out in pharmaceuticals, for instance. We have regulations in the aviation industry, we have regulations in the automobile industry, and in many ways, AI in the R&D process doesn't change that — maybe it should, people talk about, can you actually accelerate the process of approving a drug, for instance, but that wasn't the thing that we studied. In some ways, those processes are applied now, already, so that's something that doesn't necessarily have to changeThat said, are some of these potential innovations gated by approval processes or clinical trials processes? Absolutely. In some of those cases, the clinical trials process gait is not necessarily a regulation, but we know there's a big problem just finding enough potential subjects in order to do clinical trials. That's not a regulatory problem, that's a problem of finding people who are good candidates for actually testing these drugs.So yes, in some cases, even if we were able to double the amount of candidates that can go through the funnel on a number of these things, there will be these exogenous issues that would constrain society's ability to bring these to market. So that just says, you squeeze the balloon here and it opens up there, but let's go solve each of these problems, and one of the problems that we said that AI can help solve is increasing the number of things that you could potentially put into market if it can get past the other necessities.For a general public where so much of what they're hearing about AI tends to be about job loss, or are they stealing copyrighted material, or, yeah, people talk about these huge advances, but they're not seeing them yet. What is your elevator optimistic pitch why you may be worried about the impact of AI, but here's why I'm excited about it? Why are you excited by it?By the way, I think all those things are really important. All of those concerns, and how do we reskill the workforce, all those things, and we've done work on that as well. But the thing that I'm excited about is we need innovation, we need new ideas, we need scientific advancements, and engineering that turns them into products in order for us to improve their human condition, whether it's living longer lives, or living higher quality life, whether it's having the energy, whether it's to be able to support that in a way that doesn't cause other problems. All of those things, we need to have them, and what we've discovered is AI is one of those things that can produce potentially more of those ideas that can underpin, hopefully, an improved quality of life for us and our children.On sale everywhere The Conservative Futurist: How To Create the Sci-Fi World We Were PromisedMicro Reads▶ Economics* The Tariffs Kicked In. The Sky Didn't Fall. Were the Economists Wrong? - NYT Opinion* AI Disruption Is Coming for These 7 Jobs, Microsoft Says - Barron's* One Way to Ease the US Debt Crisis? Productivity - Bberg Opinion* So far, only one-third of Americans have ever used AI for work - Ars▶ Business* Meta and Microsoft Keep Their License to Spend - WSJ* Meta Pivots on AI Under the Cover of a Superb Quarter - Bberg Opinion* Will Mark Zuckerberg's secret, multibillion-dollar AI plan win over Wall Street? - FT* The AI Company Capitalizing on Our Obsession With Excel - WSJ* $15 billion in NIH funding frozen, then thawed Tuesday in ongoing power war - Ars* Mark Zuckerberg promises you can trust him with superintelligent AI - The Verge* AI Finance App Ramp Is Valued at $22.5 Billion in Funding Round - WSJ▶ Policy/Politics* Trump's Tariff Authority Is Tested in Court as Deadline on Trade Deals Looms - WSJ* China is betting on a real-world use of AI to challenge U.S. control - Wapo▶ AI/Digital* ‘Superintelligence' Will Create a New Era of Empowerment, Mark Zuckerberg Says - NYT* How Exposed Are UK Jobs to Generative AI? Developing and Applying a Novel Task-Based Index - Arxiv* Mark Zuckerberg Details Meta's Plan for Self-Improving, Superintelligent AI - Wired* A Catholic AI app promises answers for the faithful. Can it succeed? - Wapo* Power Hungry: How Ai Will Drive Energy Demand - SSRN* The two people shaping the future of OpenAI's research - MIT* Task-based returns to generative AI: Evidence from a central bank - CEPR▶ Biotech/Health* How to detect consciousness in people, animals and maybe even AI - Nature* Why living in a volatile age may make our brains truly innovative - NS▶ Clean Energy/Climate* The US must return to its roots as a nation of doers - FT* How Trump Rocked EV Charging Startups - Heatmap* Countries Promise Trump to Buy U.S. Gas, and Leave the Details for Later - NYT* Startup begins work on novel US fusion power plant. Yes, fusion. - E&E* Scientists Say New Government Climate Report Twists Their Work - Wired▶ Robotics/Drones/AVs* The grand challenges of learning medical robot autonomy - Science* Coal-Powered AI Robots Are a Dirty Fantasy - Bberg Opinion▶ Up Wing/Down Wing* A Revolutionary Reflection - WSJ Opinion* Why Did the Two Koreas Diverge? - SSRN* The best new science fiction books of August 2025 - NS* As measles spreads, old vaccination canards do too - FT Faster, Please! is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit fasterplease.substack.com/subscribe

BEST OF TSTSHOW 1: In 2008 the Bill and Melinda Gates Foundation financed Jichi Medical University in Japan to develop “a mosquito that can produce and secrete a malaria vaccine protein.” The initiative was aimed at creating a “flying syringe, to deliver protective vaccine via saliva.” In 2010 they gave money to UK-based biotech company Oxitec to develop genetically modified mosquitoes that could be lethal to carriers of dengue, zika, and yellow fever. Science Magazine published a report that year on this Japanese research and discussed what they called “flying vaccinators.” In 2015 the people of Florida, set to be the Oxitec testing ground, signed a petition against such open-air lab trials. In 2021 the trial proceeded regardless and in April 2022 Nature published a report on the results which found that although mosquitoes died in large numbers there was no reduction in disease spread or need for pesticides, which often cause the very symptoms of the diseases. A few days ago a mosquito-malaria-vaccine trial was carried out in Washington State. Of 14 participants, 7 were diagnosed with malaria leading researchers to declare their mosquito-vaccine was 50% effective. However, they made no mention of how the other half of the group could be exposed to ‘malaria' and yet not develop the disease with its vague ‘symptom complex' list. There is no question why such a malaria vaccine should be tested in the U.S. where cases rarely top 2,000 and where death rarely reaches double digits. Meanwhile, Africa is home to 95% of cases and 96% of deaths, while India is home to most of the world's polio. It is likely these ‘disease' are caused by environment, as demonstrated by official WHO data, rather than tiny invisible particles. While focus has been on the mosquito, the NIH and B&MGF have also been researching a needle-less vaccine. Such research goes back to Spain in 1999 where researchers were able to spread vaccine-induced antibodies to non-vaccinated rabbits via vaccinated rabbits. All was done in natural interaction without needle, misquotes, or any other tool. SHOW 2: Malaria is supposedly on the rise in the United States, where seven cases between Florida and Texas have been reported in the last few weeks. The CDC issued a public health alert as a result and the media collectively is spreading the terror of malaria with graphs, charts, stories, and symptoms. The strange thing is that malaria is always present, particularly in those two states, where in 2012 cases were 102 in Texas and 59 in Florida. Over the years those numbers went up and down, peaking in 2019 and then dropping significantly in 2020. This is why the media can claim cases are on the rise even if they are below the previous decade peak. From NPR to the New Scientist there are, of course, solutions to this terrible outbreak that isn't much of an outbreak: vaccines and genetically modified mosquitoes that could produce antibodies against malaria parasite. However, these same genetically modified insects have been in development since 2008 and were released in Florida after 2015. They were created with money from the B&MGF: “a mosquito that can produce and secrete a malaria vaccine protein.” But what if gm-mosquitoes are another alternative lab-leak theory? Malaria's symptoms are themselves invariably described in the same way that heat stroke symptoms are: headaches, fever, muscle aches, nausea, etc. Any mosquito issue, genetically modified or otherwise, can of course be treated with new drugs and chemicals, like the Pyriproxyfen that caused Microcephaly which was blamed on zika and mosquitos. *The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKWEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

Today on MetroNews the Morning: --A former child care worker in Kanawha County enters a plea to allegations of abuse--Capito calls on the White House to restore NIH funding--The new head of the West Virginia GOP talks about the party's future--In Sports: Best Virginia advances into the semi-finals of the TBT in Charleston 

Today on the Federal Drive with Terry Gerton The Director of the NIH joins me amid growing controversy over grant terminations, the Bethesda Declaration, and what it will take to make America healthy What happens when the federal government tries to centralize how it buys everything? A bold new research effort could offer hope to more than 20 million Americans living with brain damageSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The NIH is facing growing backlash over canceled research grants, internal pushback, and sweeping policy changes under the Trump administration. Just last week, the administration asked the Supreme Court to block a federal order that would force the agency to reinstate grants it cut over conflicts with its stance on diversity, equity, and inclusion. With billions in funding at stake, NIH Director Dr. Jay Bhattacharya joins us to break down what it all means for researchers, institutions, and the patients who rely on them.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Uber is the newest example of a consumer technology company entering into a government-wide arrangement with the General Services Administration, which negotiated the pact on behalf of every federal agency.Frank Konkel, editor-in-chief for all GovExec publications including WT, joins for this episode to break down the finer details of that agreement and how contractors are a part of it too. Then there is the bigger picture theme for Frank and Ross to talk about: how GSA views it as fitting into the agency's OneGov strategy for more consolidated buys of common tech goods and services.Which also was the subject of Frank's interview with GSA's deputy administrator Stephen Ehikian at GovExec's Government Efficiency Summit on July 17. Frank and Ross share their takeaways from that conversation with each other.Click here to watch the Summit, which was recorded by C-SPAN.WT 360: All roads lead back to GSA in this ‘Editor's Summit' episodeGSA, Uber partner to cut travel costs for feds, military and select contractorsGSA's vision for procurement is about having 'one wallet'GSA plans to optimize operations following cost-cutting, agency head saysNew OMB memo lays out GSA's plan to consolidate contractsIndustry awaits significant disruption as GSA works on contract takeoversGSA prepping plans to move NASA SEWP and NIH contract vehicles under its managementGSA's procurement chief details administration's acquisition reform plansGSA unveils new unified procurement strategyANALYSIS: GSA's new procurement strategy begins with consumer tech

Send us a textGlobal Liver Institute President and CEO Larry Holden joins Roger Green to discuss recent Washington political and regulatory activities, their potential impact on the liver community, and ways we can respond.Larry starts by acknowledging that we are in for "dark times" under the current administration and describes some current government actions that are causing major setbacks, as well as others that have the potential to do so. Specifically, he details the challenges caused by budget cuts, reallocation of funds away from major universities, staff reductions and, along with them, a loss of expertise in technical areas where knowledge and experience are pivotal.Without minimizing these challenges, Larry proceeds to suggest actions that individuals and organizations can take to reduce losses to the greatest extent possible — and even create some "wins" — for people living with liver disease. He describes tactics for giving legislators something they value (mainly publicity and contacts) to build a relationship, gain access and create a sympathetic ear for liver community messages. The conversation itself shifts back and forth between some of the current challenges and the steps advocates can take to mitigate losses and, whenever possible, achieve "wins." Sometimes discouraging, sometimes educational, this is an essential conversation for all current and potential advocates for liver patients to hear.

If you're struggling, consider therapy with our sponsor. Visit https://betterhelp.com/almanac for a discount on your first month of therapy.If you have questions about the brand relating to how the therapists are credentialed, their privacy policy, or therapist compensation, here is an overview written by the YouTube creators behind the channel Cinema Therapy that goes into these topics: https://www.reddit.com/r/cinema_therapy/comments/1dpriql/addressing_the_betterhelp_concerns_headon_deep/ Hello my dear poison friends! We are overdue for a talk on current affairs in America with RFK Jr. (Robert F. Kennedy, Jr) as the nation's Secretary of Health and Human Services. We have discussed the creation of the FDA and history of toxins in foods, beverages, and medications prior to such in our episode on the Poison Squad. Now, the FDA, CDC, NIH, and some other organizations important for the structure and future of healthcare are under the direction of a man who has repeatedly lied and spouted misinformation about vaccines, cancer, Covid, AIDS, various medications, and the like. He has promoted some dangerous conspiracy theories and has no education or experience in healthcare whatsoever. In this first part, we are looking into his background a bit and getting into some of the changes already under way under his leadership. We also need to cover some of the conspiracy theories, because he will act on what he believes and it gets pretty crazy. I wanted this to be a one episode subject, but there is just so much to talk about. Thank you to all of our listeners and supporters! Please feel free to leave a comment or send us a DM for any questions, suggestions, or just to say, "hi."Support us on Patreon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/thepoisonersalmanac⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Merch-⁠⁠⁠⁠⁠⁠⁠⁠https://poisonersalmanac.com/⁠⁠⁠⁠⁠⁠⁠⁠Follow us on socials:The Poisoner's Almanac on IG-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/poisoners_almanac?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube-⁠⁠⁠⁠⁠⁠⁠⁠https://youtube.com/@thepoisonersalmanac-m5q?si=16JV_ZKhpGaLyM73⁠⁠⁠⁠⁠⁠⁠⁠Also, look for the Poisoner's Almanac TikTok- ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@poisonersalmanacp?_t=ZT-8wdYQyXhKbm&_r=1⁠⁠⁠⁠⁠⁠⁠⁠⁠Adam-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@studiesshow?is_from_webapp=1&sender_device=pc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Becca-⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.tiktok.com/@yobec0?is_from_webapp=1&sender_device=pc⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Dr. Rebecca Corwin is a former university professor andRegistered Dietitian Nutritionist with a successful career inresearch and education. She earned degrees in education,clinical dietetics, behavioral sciences, and biopsychology,completing postdoctoral training at Cornell University andthe NIH. Over 23 years at Penn State, she rose to fullProfessor in Nutritional Sciences, published 59 peer-reviewed articles and several book chapters, and mentoredstudents at all levels. Though an agnostic for much of herlife, she became a passionate follower of Christ in 2006,dedicating herself to studying, teaching, and writing aboutHis Word. Dr. Corwin now serves in multiple leadership roleswithin her church and recently published Arise and Eat!, herfirst full-length book. To learn more about Dr Corwin, go to ariseandeat.com Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

This Day in Legal History: National Security Act of 1947On this day in legal history, July 25, 1947, Congress passed the National Security Act of 1947, fundamentally reshaping the American national security infrastructure in the wake of World War II. The legislation created a unified framework to coordinate defense and intelligence operations, aiming to prevent the bureaucratic fragmentation that had plagued wartime decision-making. One of its central provisions was the formation of the National Security Council (NSC), designed to advise the president on domestic, foreign, and military policies related to national security.The Act also established the Central Intelligence Agency (CIA), which replaced the wartime Office of Strategic Services (OSS) and became the first peacetime intelligence agency tasked with gathering, analyzing, and coordinating intelligence. Additionally, it created the National Military Establishment (later renamed the Department of Defense in 1949), which consolidated the War Department and the Navy Department under a single executive authority.Within the National Military Establishment, the Act preserved the autonomy of the Army and Navy while officially creating a separate branch: the United States Air Force. It also formalized the Joint Chiefs of Staff to provide coordinated military advice to civilian leadership. These structural reforms sought to ensure more cohesive planning and execution of U.S. defense policy during a time of growing Cold War tensions.The legislation marked a profound shift in how the federal government approached global strategy, institutionalizing the military-intelligence bureaucracy that would define American power projection for decades. It also laid the legal groundwork for the modern national security state, with broad implications for executive authority, covert operations, and civil-military relations. As Cold War dynamics evolved, the institutions born from this Act became central to both overt diplomacy and covert action around the world.Ghislaine Maxwell, currently serving a 20-year sentence for aiding Jeffrey Epstein's abuse of minors, is petitioning the U.S. Supreme Court to overturn her conviction. Her legal team argues that a 2007 non-prosecution agreement made with Epstein in Florida should have shielded her and other associates from future federal prosecution. The case raises a significant legal issue: whether plea deals made by one U.S. Attorney's Office bind other federal jurisdictions. This question has divided circuit courts, increasing the chances the Supreme Court might take up the case when justices return from summer recess in late September.The Justice Department under Trump acknowledged the legal split but urged the Court to deny Maxwell's appeal, arguing that plea agreements are binding only between the negotiating parties. Maxwell's defense contends the 2007 deal's broad language promised immunity for co-conspirators nationwide, and that allowing prosecutors to renege undermines trust in the justice system. The National Association of Criminal Defense Lawyers supports her petition, citing the widespread use of plea agreements in American jurisprudence.The case unfolds amid renewed political pressure over Epstein-related disclosures, with Trump's administration walking back earlier commitments to release more records. The political sensitivity may affect the Supreme Court's willingness to get involved, especially given the presence of three Trump-appointed justices. Columbia Law professor Daniel Richman noted the unusual breadth of Epstein's original deal might make this a poor case for setting a national precedent, despite its legal significance.Amid Epstein furor, Ghislaine Maxwell seeks relief from US Supreme Court | ReutersThe Trump administration has asked the U.S. Supreme Court to allow it to implement major funding cuts to National Institutes of Health (NIH) grants, arguing the cuts align with its broader effort to dismantle federal diversity, equity, and inclusion (DEI) programs. A lower court had blocked the move in June, with U.S. District Judge William Young ruling that the cuts were unlawfully arbitrary and lacked clear justification, violating administrative law. The decision came after lawsuits from a coalition of researchers, public health groups, and 16 states led by Democratic administrations, who argued the grant cancellations were politically motivated and targeted research associated with DEI or gender identity.The administration contends that continuing to pay the $783 million in grants contradicts its policy goals. The Justice Department is also challenging the venue of the lawsuits, arguing they should have been brought in the Court of Federal Claims, which specializes in monetary claims against the federal government. The 1st U.S. Circuit Court of Appeals recently rejected that argument, refusing to pause Judge Young's ruling.Judge Young, despite being a Reagan appointee, sharply criticized the administration's actions as lacking any rational explanation and as ideologically driven. He noted that officials failed to define DEI while broadly discrediting grant-supported research without evidence. Critics, including NIH employees and scientists, have warned that the cuts undermine scientific integrity and public health.The Supreme Court, now with a 6-3 conservative majority, has been receptive to Trump administration appeals in similar cases. In April, it allowed comparable cuts to teacher training grants to proceed. The administration hopes for a similar result in this case.Trump administration asks US Supreme Court to allow NIH diversity-related cuts | ReutersGlass Lewis and Institutional Shareholder Services (ISS), two leading proxy advisory firms, have filed lawsuits against Texas over a new state law restricting their ability to advise shareholders on environmental, social, governance (ESG), and diversity, equity, and inclusion (DEI) matters. Proxy advisors provide independent recommendations to institutional investors—such as pension funds and asset managers—on how to vote on issues at shareholder meetings, including board elections, executive compensation, and corporate policies. This means their influence is significant in shaping corporate governance across markets.The new Texas law, signed by Governor Greg Abbott, requires these advisors to include disclaimers stating their recommendations may not be in the financial interest of shareholders and to back up ESG or DEI-related advice with financial analysis. Glass Lewis and ISS argue the law violates their First Amendment rights by forcing them to include government-mandated speech that contradicts their independent analysis and perspectives.Filed in federal court in Austin, the lawsuits name Attorney General Ken Paxton as the sole defendant. Both firms contend the law is politically motivated and will damage their reputations, cost them clients, and undermine shareholder oversight of corporate boards. ISS also criticized the law as serving to protect corporate executives from accountability, labeling it "anti-capitalist" and counter to shareholder interests.The legal challenge comes amid a broader rollback of corporate DEI programs nationwide and is part of a trend in Republican-led states to push back against what they see as left-leaning influence in financial decision-making. The law is scheduled to take effect on September 1, unless blocked by the court.Glass Lewis, ISS sue Texas over law limiting DEI, ESG proxy advice | ReutersThis week's closing theme is by Enrique Granados.This week's closing theme is Granados' masterwork Goyescas, Op. 11, a piano suite composed in 1911 and widely regarded as the Spanish composer's magnum opus. Subtitled Los majos enamorados (The Gallants in Love), the suite captures the spirit and elegance of 18th-century Madrid, evoking a romanticized world of passionate young lovers, elaborate dress, and melancholic reverie. Granados drew inspiration from the art of Francisco Goya, though the individual pieces are not linked directly to specific paintings. Instead, they are tonal impressions—musical vignettes steeped in the colors and textures of Goya's Spain.Goyescas is divided into two books. Granados premiered Book I on March 11, 1911, at the Palau de la Música Catalana in Barcelona, showcasing his own virtuosic pianism. Book II followed in December of that year and was first performed in Paris at the Salle Pleyel on April 2, 1914. Each movement in the suite is rich with rhythmic flair, lyrical warmth, and emotional depth, capturing the elegance of Spanish courtship rituals and the melancholy undercurrents of unfulfilled longing.The suite's most famous piece, Quejas, o La Maja y el Ruiseñor (Lament, or The Maiden and the Nightingale), would later be famously echoed in the song “Bésame Mucho.” Granados' idiomatic use of ornamentation, rubato, and folkloric rhythms set a high watermark for Spanish piano music and influenced later composers such as Albéniz and Falla. Through Goyescas, Granados created a work that is both a tribute to Goya's vision and a deeply personal expression of turn-of-the-century Spanish romanticism.Without further ado, Enrique Granados' The Gallants in Love, the third movement, El Fandango del Candil. Enjoy! This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Abdul and Katelyn discuss the latest in public health including: Congress' vote to reinstate $400 million in funding for global AIDS treatment Trump's budget proposal to cut 40% of the NIH budget The health differences in Coca Cola sweetened with sugar vs high fructose corn syrup Why heart attack is no longer the leading cause of death in the US A comprehensive review of GI cancer research that show sharp rise in cases among young people Then Abdul talks to Dr. Elaine Batchlor from Martin Luther King Jr Community Healthcare about how the impending Medicaid cuts will strain hospitals that serve low-income patients. Check out our shop at store.americadissected.com for our new America Dissected merch – including logo shirts, hoodies and mugs. And don't miss our “Vaccines Matter. Science Works.” t-shirts! This show would not be possible without the generous support of our sponsors. America Dissected invites you to check them out. This episode was brought to you by: NPR Life Kit: Listen now to the Life Kit podcast from NPR. Quince: Go to Quince.com/AD for free shipping on your order and 365-day returns.

What if the spaces we inhabit could actually help us heal? In this episode, we speak with Dr. Esther Sternberg, a pioneering physician and scientist whose groundbreaking research bridges neuroscience, architecture, and integrative medicine. Drawing from her work at the NIH and the Andrew Weil Center for Integrative Medicine, Dr. Sternberg reveals how elements like light, air quality, noise, and spatial design can profoundly affect our stress levels, focus, and overall health. We explore how thoughtfully designed environments—whether offices, hospitals, or senior living spaces—can support emotional and physical well-being. Through the lens of integrative health, which considers sleep, movement, nutrition, relationships, spirituality, and the built environment, Dr. Sternberg offers a powerful case for reimagining the spaces around us to truly support how we live, work, and heal.

Rightio, this is Martin doing the show notes—not Jason! I may be absent from this recording (apologies) but you can be sure that I've used the notes as my own stream of thoughts in the first person. Enjoy! Also, I'll be including a set of Jason's favourite punctuation marks, just to mess with the formatting a bit. Already off the Rails 00:00:00 Linear editing (https://www.motionelements.com/blog/articles/understanding-linear-vs-non-linear-editing) I was at a pre-booked show with my family at the Illawarra Performing Arts Centre since we had to move recording times! Although I value to the use of public transport I don't enjoy buses. THIS IS ALREADY ALL OVER THE PLACE. Here's the first set! - (hyphen) – (en dash) — (em dash) One Prime Plus 00:02:26 Here's the site to join! (https://oneprimeplus.com) Insurance in Australia (https://en.wikipedia.org/wiki/Insurance_in_Australia) That link above isn't necessary; I just thought I'd waste your time. Follow-up 00:03:59 Cronut (https://en.wikipedia.org/wiki/Cronut) Cruffin (https://en.wikipedia.org/wiki/Cruffin) Yes, I love being right. ... (ellipsis) ... Hipod 00:05:01 iPod Hi-Fi (https://apple.fandom.com/wiki/IPod_Hi-Fi) Peer pressure?! I call bullshit, Andrew! WiiM Pro and Plus (https://wiimhome.com/wiimpro/overview) Jason's solution: MORE WiiM!

We are back with GOOD news! Today Steve and I chat about the appropriations process (because if you thought the Big Beautiful Bill was the end of the conversation you were wrong) and how the committees are being less slash and burn in their proposals. We also talk about some upcoming changes to NIH submission policy (no more submitting 6+ applications as PI or mPI per year) and their AI policy. Check it out!Follow me on Twitter!Interested in Hanover helping you with your grants? Check out our website for more information.

Today on the show  the First Circuit is reversing DOGE's “DEI” cuts at NIH. Trump is suing the Wall Street Journal for defamatory reporting that he was friends with that pedophile he used to party with all the time. And trial courts are calling SCOTUS's shadow docket bluff. Plus, Alina Habba is headed for the exit.   Links:   SCOTUS Shadow Docket Order Dept. of Education v. California https://www.supremecourt.gov/opinions/24pdf/24a910_f2bh.pdf   American Public Health Association v. National Institutes of Health  https://www.courtlistener.com/docket/70621936/american-public-health-association-v-national-institutes-of-health/   CREW v. OMB https://www.courtlistener.com/docket/69858087/citizens-for-responsibility-and-ethics-in-washington-v-office-of/   Show Links: https://www.lawandchaospod.com/ BlueSky: @LawAndChaosPod Threads: @LawAndChaosPod Twitter: @LawAndChaosPod  

Research funded by the federal government has been crucial in many of the defining technologies of our time: the internet, A.I., crispr, Ozempic, and the mRNA vaccines first used widely in the COVID pandemic. Between 2010 and 2019, more than 350 drugs were approved in the United States, and virtually all of them could trace their roots to the National Institutes of Health (NIH). Now this administration is endangering our health by cutting funds to academic medical centers. Moreover, there are threats to Medicaid, as well as ongoing cuts to the Centers for Disease Control (CDC). Many universities have paused hiring due to the uncertainty at the NIH and are curtailing graduate programs. Biotech investors are warning of a contraction in medical innovation. NIH grants have been terminated on ideological grounds, which have resulted in clinical trials shutting down. Global health programs worldwide have been cut. A discussion on these destructive policies on medicine in our country is needed. About the Speaker Monica Gandhi M.D., M.P.H., is a professor of medicine and associate chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the director of the UCSF Center for AIDS Research (CFAR) and the medical director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. She serves as the associate program director of the ID fellowship at UCSF. Her research focuses on HIV treatment and prevention optimization, HIV and women, adherence measurement in HIV and TB, adherence interventions, and on optimizing the use of long-acting antiretroviral therapy (ART). She is a long-standing NIH-funded researcher. Commonwealth Club World Affairs of California is a nonprofit public forum; we welcome donations made during registration to support the production of our programming. A Health & Medicine Member-led Forum program. Forums and Chapters at the Club are organized and run by volunteer programmers who are members of The Commonwealth Club, and they cover a diverse range of topics. Learn more about our Forums. Commonwealth Club World Affairs is a public forum. Any views expressed in our programs are those of the speakers and not of Commonwealth Club World Affairs. OrganizerMichael Baker  Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textDid you know that the trillions of microbes in your gut could be the key to weight loss, better energy, fewer aches and pains - and even reversing chronic disease? In this episode, gut health pioneer Martha Carlin joins Coach Kevin to break down why your microbiome is the hidden root of so many modern health issues - and what you can do to restore it.  Whether you're dealing with bloating, fatigue, brain fog, or stubborn weight that just won't budge - this conversation will give you a fresh (and hopeful) perspective on what's really going on inside your body. And more importantly - how to fix it. 

1. Senator Rand Paul's Criminal Referral of Dr. Anthony Fauci Context: Senator Paul has reissued a criminal referral to the DOJ against Dr. Fauci, citing perjury related to his 2021 Senate testimony on gain-of-function research in Wuhan. Controversy: The referral is tied to President Biden’s use of an autopen to sign pardons, including one for Fauci. If the autopen-signed pardons are ruled invalid, Fauci could face prosecution. Allegations: Fauci allegedly misled Congress about NIH funding for gain-of-function research. Political Angle: The Trump administration is portrayed as cooperative in pursuing the investigation, while the Biden administration is accused of obstruction. 2. Supreme Court Ruling on the Department of Education Issue: The Trump administration’s plan to shut down the Department of Education and return control to the states. Ruling: The Supreme Court (6-3 decision) lifted an injunction, allowing layoffs of over 1,300 employees and enabling the department’s closure to proceed. Reactions: Supporters: Frame it as a win for parents, students, and educational reform. Dissenters: Warn of executive overreach and erosion of separation of powers. Next Steps: Programs like special education and student loans are being transferred to other federal agencies. Please Hit Subscribe to this podcast Right Now. Also Please Subscribe to the Ben Ferguson Show Podcast and Verdict with Ted Cruz Wherever You get You're Podcasts. Thanks for Listening #seanhannity #hannity #marklevin #levin #charliekirk #megynkelly #tucker #tuckercarlson #glennbeck #benshapiro #shapiro #trump #sexton #bucksexton#rushlimbaugh #limbaugh #whitehouse #senate #congress #thehouse #democrats#republicans #conservative #senator #congressman #congressmen #congresswoman #capitol #president #vicepresident #POTUS #presidentoftheunitedstatesofamerica#SCOTUS #Supremecourt #DonaldTrump #PresidentDonaldTrump #DT #TedCruz #Benferguson #Verdict #maga #presidenttrump #47 #the47morningupdate #donaldtrump #trump #news #trumpnews #Benferguson #breaking #breakingnews #morningupdateYouTube: https://www.youtube.com/@VerdictwithTedCruzSee omnystudio.com/listener for privacy information.

Last week, Abdul El-Sayed sat down with Donna to discuss his candidacy for the U.S. Senate!Abdul is running for the U.S. Senate because he believes life in Michigan shouldn't be this hard — or this expensive. After a successful career of making government work for Michiganders, he wants to take his vision to Washington and make the United States Senate work for you. He was born and raised in southeast Michigan and proudly attended public schools where he captained his high school football, wrestling, and lacrosse teams. Abdul was raised by his father, Mohamed, an Egyptian immigrant, and his stepmom, Jackie, whose family has lived in Gratiot County, Michigan, since the 1800s. he graduated from the university of michigan with the highest distinction and played on the wolverines men's lacrosse team. Abdul earned his medical degree from Columbia University on an NIH-funded fellowship and a second doctorate at Oxford University as a Rhodes Scholar. Abdul currently lives in Ann Arbor with his wife, Sarah, and their two brilliant young daughters, Emmalee and Serene.To learn more about Adbul El-Sayed and his vision for Michigan, click here.Support the showFollow us on Instagram, Facebook and Twitter.

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell disease, a blood disorder that affects roughly 100,000 people in the U.S. According to the CDC, 90% of them are Black. Ali Rogin speaks with Dr. Charity Oyedeji, a Duke University hematologist whose research grant was terminated, to learn more. PBS News is supported by - https://www.pbs.org/newshour/about/funders

When it comes to medical science, there's never been a better time to be alive than now… other than maybe a few months ago before the new Trump administration. Americans today are living longer than ever before, and that's owed in no small part to the National Institutes of Health—a government organization that has been responsible for some of the most significant biomedical advancements in the history of healthcare. Unfortunately, the Trump administration just virtually annihilated the NIH, and sentient gob of clay and anti-vax charlatan RFK Jr. is now in charge of the future of American health. To figure how how to navigate this insane dichotomy of medical potential and squandered medical possibility, Adam speaks with Dr. Eric Topol, a cardiologist and scientist, and director of the Scripps Research Translational Institute. Dr. Topol's book, Super Agers: An Evidence-Based Approach to Longevity, explores the cutting edge advancements in living longer, healthier lives—advancements which are now in jeopardy. Find Dr. Topol's book at factuallypod.com/books--SUPPORT THE SHOW ON PATREON: https://www.patreon.com/adamconoverSEE ADAM ON TOUR: https://www.adamconover.net/tourdates/SUBSCRIBE to and RATE Factually! on:» Apple Podcasts: https://podcasts.apple.com/us/podcast/factually-with-adam-conover/id1463460577» Spotify: https://open.spotify.com/show/0fK8WJw4ffMc2NWydBlDyJAbout Headgum: Headgum is an LA & NY-based podcast network creating premium podcasts with the funniest, most engaging voices in comedy to achieve one goal: Making our audience and ourselves laugh. Listen to our shows at https://www.headgum.com.» SUBSCRIBE to Headgum: https://www.youtube.com/c/HeadGum?sub_confirmation=1» FOLLOW us on Twitter: http://twitter.com/headgum» FOLLOW us on Instagram: https://instagram.com/headgum/» FOLLOW us on TikTok: https://www.tiktok.com/@headgum» Advertise on Factually! via Gumball.fmSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.